Charles River Laboratories International (CRL) 10-Q6 Nov 242024 Q3 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 28, 2024	Oct. 26, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 28, 2024
Document Transition Report	false
Entity File Number	001-15943
Entity Registrant Name	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	06-1397316
Entity Address, Address Line One	251 Ballardvale Street
Entity Address, City or Town	Wilmington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01887
City Area Code	781
Local Phone Number	222-6000
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	CRL
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		51,136,178
Entity Central Index Key	0001100682
Current Fiscal Year End Date	--12-28
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Total revenue	$ 1,009,763	$ 1,026,623	$ 3,047,440	$ 3,115,933
Costs and expenses
Cost of revenue (excluding amortization of intangible assets)	660,742	664,783	1,999,863	1,977,462
Selling, general and administrative	199,213	176,109	555,295	550,713
Amortization of intangible assets	32,403	34,229	97,248	103,419
Operating income	117,405	151,502	395,034	484,339
Other income (expense)
Interest income	1,528	1,373	6,740	3,605
Interest expense	(30,284)	(33,742)	(98,054)	(103,166)
Other income (expense), net	2,592	(6,260)	6,185	(12,200)
Income before income taxes	91,241	112,873	309,905	372,578
Provision for income taxes	20,946	24,852	70,867	81,160
Net income	70,295	88,021	239,038	291,418
Less: Net income attributable to noncontrolling interests	638	632	2,340	3,878
Net income attributable to Charles River Laboratories International Inc.	69,657	87,389	236,698	287,540
Calculation of net income per share attributable to Charles River Laboratories International Inc. common shareholders
Net income attributable to Charles River Laboratories International Inc.	69,657	87,389	236,698	287,540
Less: Adjustment of redeemable noncontrolling interest	379	0	1,081	0
Less: Incremental dividends attributed to noncontrolling interest holders	599	0	9,621	0
Net income available to Charles River Laboratories International Inc. common shareholders	$ 68,679	$ 87,389	$ 225,996	$ 287,540
Earnings per common share
Basic (in dollars per share)	$ 1.34	$ 1.70	$ 4.39	$ 5.62
Diluted (in dollars per share)	$ 1.33	$ 1.69	$ 4.37	$ 5.58
Weighted-average number of common shares outstanding
Basic (in shares)	51,394	51,283	51,461	51,199
Diluted (in shares)	51,583	51,607	51,713	51,493
Service
Total revenue	$ 832,463	$ 869,759	$ 2,492,225	$ 2,602,016
Costs and expenses
Cost of revenue (excluding amortization of intangible assets)	568,699	587,560	1,724,246	1,731,136
Product
Total revenue	177,300	156,864	555,215	513,917
Costs and expenses
Cost of revenue (excluding amortization of intangible assets)	$ 92,043	$ 77,223	$ 275,617	$ 246,326

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Net income	$ 70,295	$ 88,021	$ 239,038	$ 291,418
Other comprehensive income (loss):
Foreign currency translation adjustment	85,018	(63,997)	500	(17,457)
Amortization of net loss, settlement losses, and prior service benefit included in total cost for pension and other post-retirement benefit plans	352	177	1,038	521
Unrealized gains (losses) on hedging instruments	(1,060)	539	(688)	5,183
Other comprehensive income (loss), before income taxes	84,310	(63,281)	850	(11,753)
Less: Income tax expense (benefit) related to items of other comprehensive income	8,348	(3,292)	848	(3,393)
Comprehensive income, net of income taxes	146,257	28,032	239,040	283,058
Less: Comprehensive income (loss) related to noncontrolling interests, net of income taxes	(238)	440	(1,214)	1,527
Comprehensive income attributable to Charles River Laboratories International, Inc., net of income taxes	$ 146,495	$ 27,592	$ 240,254	$ 281,531

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 28, 2024	Dec. 30, 2023
Current assets:
Cash and cash equivalents	$ 210,171	$ 276,771
Trade receivables and contract assets, net of allowances for credit losses of $23,877 and $25,722, respectively	754,207	780,375
Inventories	336,200	380,259
Prepaid assets	92,631	87,879
Other current assets	101,514	83,378
Total current assets	1,494,723	1,608,662
Property, plant and equipment, net	1,639,978	1,639,741
Venture capital and strategic equity investments	235,987	243,811
Operating lease right-of-use assets, net	385,133	394,029
Goodwill	3,124,592	3,095,045
Intangible assets, net	778,461	864,051
Deferred tax assets	37,963	40,279
Other assets	307,005	309,383
Total assets	8,003,842	8,195,001
Current liabilities:
Accounts payable	135,963	168,937
Accrued compensation	211,077	213,290
Deferred revenue	251,968	241,820
Accrued liabilities	208,124	227,825
Other current liabilities	205,089	203,210
Total current liabilities	1,012,221	1,055,082
Long-term debt, net and finance leases	2,326,653	2,647,147
Operating lease right-of-use liabilities	432,836	419,234
Deferred tax liabilities	167,746	191,349
Other long-term liabilities	236,669	223,191
Total liabilities	4,176,125	4,536,003
Commitments and contingencies (Notes 2, 11, 13, and 15)
Redeemable noncontrolling interest	40,590	56,722
Equity:
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.01 par value; 120,000 shares authorized; 51,718 shares issued and 51,134 shares outstanding as of September 28, 2024, and 51,338 shares issued and outstanding as of December 30, 2023	517	513
Additional paid-in capital	1,971,413	1,905,578
Retained earnings	2,122,835	1,887,218
Treasury stock, at cost, 584 and zero shares, as of September 28, 2024 and December 30, 2023, respectively	(119,621)	0
Accumulated other comprehensive loss	(192,871)	(196,427)
Total Charles River Laboratories International, Inc. equity	3,782,273	3,596,882
Nonredeemable noncontrolling interests	4,854	5,394
Total equity	3,787,127	3,602,276
Total liabilities, noncontrolling interests and equity	$ 8,003,842	$ 8,195,001

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) $ in Thousands	Sep. 28, 2024	Dec. 30, 2023
Statement of Financial Position [Abstract]
Less: Allowance for credit losses	$ 23,877	$ 25,722
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	51,718,000	51,338,000
Common stock, shares outstanding (in shares)	51,134,000	51,338,000
Treasury stock, shares (in shares)	584,000	0

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023
Cash flows relating to operating activities
Net income	$ 239,038	$ 291,418
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	259,637	233,610
Stock-based compensation	52,656	52,527
Deferred income taxes	(25,988)	(28,251)
Long-lived asset impairment charges	17,339	26,202
(Gain) loss on venture capital & strategic equity investments, net	(8,788)	9,246
Provision for credit losses	8,223	11,030
Loss on divestitures, net	659	995
Other, net	20,372	6,947
Changes in assets and liabilities:
Trade receivables and contract assets, net	18,300	(59,081)
Inventories	13,789	(44,126)
Accounts payable	(7,095)	(26,531)
Accrued compensation	(1,981)	28,438
Deferred revenue	13,583	(9,997)
Customer contract deposits	14,707	(21,534)
Other assets and liabilities, net	(39,236)	(7,938)
Net cash provided by operating activities	575,215	462,955
Cash flows relating to investing activities
Acquisition of businesses and assets, net of cash acquired	(5,479)	(50,166)
Capital expenditures	(157,351)	(240,205)
Purchases of investments and contributions to venture capital investments	(45,264)	(36,322)
Proceeds from sale of investments	39,470	3,953
Other, net	(358)	(2,044)
Net cash used in investing activities	(168,982)	(324,784)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit facility	976,783	333,034
Proceeds from exercises of stock options	23,110	19,658
Payments on long-term debt, revolving credit facility, and finance lease obligations	(1,316,990)	(530,909)
Purchase of treasury stock	(119,051)	(24,016)
Payments of contingent consideration	0	(2,711)
Purchase of remaining equity interest of other redeemable noncontrolling interest	(12,000)	0
Other, net	(26,900)	(4,145)
Net cash used in financing activities	(475,048)	(209,089)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(4,025)	(4,680)
Net change in cash, cash equivalents, and restricted cash	(72,840)	(75,598)
Cash, cash equivalents, and restricted cash, beginning of period	284,480	241,214
Cash, cash equivalents, and restricted cash, end of period	$ 211,640	$ 165,616

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS (UNAUDITED) - USD ($) $ in Thousands	Total	Total Charles River Laboratories, Inc. Equity	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Noncontrolling Interest
Beginning balance at Dec. 31, 2022	$ 42,427
Increase (Decrease) in Temporary Equity
Net income	322
Other comprehensive (loss), net of tax	186
Ending balance at Apr. 01, 2023	42,935
Beginning balance (in shares) at Dec. 31, 2022			50,944,000
Beginning balance at Dec. 31, 2022	2,981,078	$ 2,976,293	$ 509	$ 1,804,940	$ 1,432,901	$ (262,057)	$ 0	$ 4,785
Beginning balance (in shares) at Dec. 31, 2022							0
Increase (Decrease) in Stockholders' Equity
Net income	103,632	103,131			103,131			501
Other comprehensive (loss), net of tax	22,933	22,933				22,933
Issuance of stock under employee compensation plans (in shares)			316,000
Issuance of stock under employee compensation plans	11,792	11,792	$ 3	11,789
Purchase of treasury shares (in shares)							78,000
Purchase of treasury shares	(19,012)	(19,012)					$ (19,012)
Stock-based compensation	13,460	13,460		13,460
Ending balance (in shares) at Apr. 01, 2023			51,260,000
Ending balance at Apr. 01, 2023	3,113,883	3,108,597	$ 512	1,830,189	1,536,032	(239,124)	$ (19,012)	5,286
Ending balance (in shares) at Apr. 01, 2023							78,000
Increase (Decrease) in Temporary Equity
Net income	1,857
Other comprehensive (loss), net of tax	(2,345)
Ending balance at Jul. 01, 2023	42,447
Increase (Decrease) in Stockholders' Equity
Net income	97,586	97,020			97,020			566
Other comprehensive (loss), net of tax	30,855	30,855				30,855
Issuance of stock under employee compensation plans (in shares)			110,000
Issuance of stock under employee compensation plans	3,927	3,927	$ 1	3,926
Purchase of treasury shares (in shares)							26,000
Purchase of treasury shares	(4,966)	(4,966)					$ (4,966)
Stock-based compensation	16,270	16,270		16,270
Ending balance (in shares) at Jul. 01, 2023			51,370,000
Ending balance at Jul. 01, 2023	3,257,555	3,251,703	$ 513	1,850,385	1,633,052	(208,269)	$ (23,978)	5,852
Ending balance (in shares) at Jul. 01, 2023							104,000
Increase (Decrease) in Temporary Equity
Net income	71
Other comprehensive (loss), net of tax	(192)
Dividends to noncontrolling interests	(2,378)
Ending balance at Sep. 30, 2023	39,948
Increase (Decrease) in Stockholders' Equity
Net income	87,950	87,389			87,389			561
Other comprehensive (loss), net of tax	(59,797)	(59,797)				(59,797)
Dividends to noncontrolling interests	(1,645)							(1,645)
Issuance of stock under employee compensation plans (in shares)			30,000
Issuance of stock under employee compensation plans	3,939	3,939	$ 1	3,938
Purchase of treasury shares	(38)	(38)					$ (38)
Stock-based compensation	22,797	22,797		22,797
Ending balance (in shares) at Sep. 30, 2023			51,400,000
Ending balance at Sep. 30, 2023	3,310,761	3,305,993	$ 514	1,877,120	1,720,441	(268,066)	$ (24,016)	4,768
Ending balance (in shares) at Sep. 30, 2023							104,000
Beginning balance at Dec. 30, 2023	56,722
Increase (Decrease) in Temporary Equity
Net income	1,201
Other comprehensive (loss), net of tax	(2,763)
Adjustment of redeemable noncontrolling interests to redemption value	4,807
Dividends to noncontrolling interests	(2,192)
Ending balance at Mar. 30, 2024	$ 57,775
Beginning balance (in shares) at Dec. 30, 2023	51,338,000		51,338,000
Beginning balance at Dec. 30, 2023	$ 3,602,276	3,596,882	$ 513	1,905,578	1,887,218	(196,427)	$ 0	5,394
Beginning balance (in shares) at Dec. 30, 2023	0						0
Increase (Decrease) in Stockholders' Equity
Net income	$ 73,281	72,960			72,960			321
Other comprehensive (loss), net of tax	(53,492)	(53,492)				(53,492)
Adjustment of redeemable noncontrolling interests to redemption value	(4,807)	(4,807)		(4,406)	(401)
Issuance of stock under employee compensation plans (in shares)			214,000
Issuance of stock under employee compensation plans	21,505	21,505	$ 2	21,503
Purchase of treasury shares (in shares)							42,000
Purchase of treasury shares	(9,351)	(9,351)					$ (9,351)
Stock-based compensation	16,738	16,738		16,738
Ending balance (in shares) at Mar. 30, 2024			51,552,000
Ending balance at Mar. 30, 2024	3,646,150	3,640,435	$ 515	1,939,413	1,959,777	(249,919)	$ (9,351)	5,715
Ending balance (in shares) at Mar. 30, 2024							42,000
Beginning balance at Dec. 30, 2023	56,722
Ending balance at Sep. 28, 2024	$ 40,590
Beginning balance (in shares) at Dec. 30, 2023	51,338,000		51,338,000
Beginning balance at Dec. 30, 2023	$ 3,602,276	3,596,882	$ 513	1,905,578	1,887,218	(196,427)	$ 0	5,394
Beginning balance (in shares) at Dec. 30, 2023	0						0
Ending balance (in shares) at Sep. 28, 2024	51,134,000		51,718,000
Ending balance at Sep. 28, 2024	$ 3,787,127	3,782,273	$ 517	1,971,413	2,122,835	(192,871)	$ (119,621)	4,854
Ending balance (in shares) at Sep. 28, 2024	584,000						584,000
Beginning balance at Mar. 30, 2024	$ 57,775
Increase (Decrease) in Temporary Equity
Net income	(332)
Other comprehensive (loss), net of tax	85
Adjustment of redeemable noncontrolling interests to redemption value	496
Purchase of remaining equity interest of other redeemable noncontrolling interest	(12,000)
Adjustment of purchase price of Noveprim redeemable noncontrolling interest	52
Ending balance at Jun. 29, 2024	46,076
Beginning balance (in shares) at Mar. 30, 2024			51,552,000
Beginning balance at Mar. 30, 2024	3,646,150	3,640,435	$ 515	1,939,413	1,959,777	(249,919)	$ (9,351)	5,715
Beginning balance (in shares) at Mar. 30, 2024							42,000
Increase (Decrease) in Stockholders' Equity
Net income	94,593	94,081			94,081			512
Other comprehensive (loss), net of tax	(19,790)	(19,790)				(19,790)
Adjustment of redeemable noncontrolling interests to redemption value	(496)	(496)		(195)	(301)
Dividends to noncontrolling interests	(1,938)							(1,938)
Issuance of stock under employee compensation plans (in shares)			144,000
Issuance of stock under employee compensation plans	826	826	$ 2	824
Purchase of treasury shares (in shares)							41,000
Purchase of treasury shares	(8,914)	(8,914)					$ (8,914)
Stock-based compensation	16,587	16,587		16,587
Ending balance (in shares) at Jun. 29, 2024			51,696,000
Ending balance at Jun. 29, 2024	3,727,018	3,722,729	$ 517	1,956,629	2,053,557	(269,709)	$ (18,265)	4,289
Ending balance (in shares) at Jun. 29, 2024							83,000
Increase (Decrease) in Temporary Equity
Net income	73
Other comprehensive (loss), net of tax	(876)
Adjustment of redeemable noncontrolling interests to redemption value	5,705
Dividends to noncontrolling interests	(10,388)
Ending balance at Sep. 28, 2024	40,590
Increase (Decrease) in Stockholders' Equity
Net income	70,222	69,657			69,657			565
Other comprehensive (loss), net of tax	76,838	76,838				76,838
Adjustment of redeemable noncontrolling interests to redemption value	(5,705)	(5,705)		(5,326)	(379)
Issuance of stock under employee compensation plans (in shares)			22,000
Issuance of stock under employee compensation plans	779	779		779
Purchase of treasury shares (in shares)							501,000
Purchase of treasury shares	(100,786)	(100,786)					$ (100,786)
Share repurchase excise tax	(570)	(570)					(570)
Stock-based compensation	$ 19,331	19,331		19,331
Ending balance (in shares) at Sep. 28, 2024	51,134,000		51,718,000
Ending balance at Sep. 28, 2024	$ 3,787,127	$ 3,782,273	$ 517	$ 1,971,413	$ 2,122,835	$ (192,871)	$ (119,621)	$ 4,854
Ending balance (in shares) at Sep. 28, 2024	584,000						584,000

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Sep. 28, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The year-end condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for fiscal year 2023 as filed with the SEC on February 14, 2024. Certain reclassifications of prior year amounts have been made to conform to the current year presentation. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations. Use of Estimates The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. Newly Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, “Improvements to Reportable Segment Disclosures (Topic 280)”. ASU 2023-07 modifies reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures on the consolidated financial statements, but does not believe there will be a material impact. In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures (Topic 740)”. ASU 2023-09 requires enhanced disclosures on income taxes paid, adds disaggregation of continuing operations before income taxes between foreign and domestic earnings and defines specific categories for the reconciliation of jurisdictional tax rate to effective tax rate. This ASU is effective for fiscal years beginning after December 15, 2024, and can be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures on the consolidated financial statements. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 10-K for fiscal year 2023 as filed with the SEC on February 14, 2024. Consolidation The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its unaudited condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Redeemable noncontrolling interests, where the noncontrolling interest holders have the ability to require the Company to purchase the remaining interests, are classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities. Intercompany balances and transactions are eliminated in consolidation. The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end. Segment Reporting The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The Company’s RMS reportable segment includes products and services offered within the Research Models, Research Model Services, and Cell Solutions. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Insourcing Solutions (IS), which provides colony management of clients’ research operations (including recruitment, training, staffing, and management services) within the clients’ facilities and utilizing the Charles River Accelerator and Development Lab (CRADL™) offering, which provides vivarium space to clients, Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models, and Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Cell Solutions, which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow. The Company’s DSA reportable segment includes Discovery Services and Safety Assessment services. The Company provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro (non-animal) and in vivo (in research models) studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO).

ACQUISITIONS AND DIVESTITURES

ACQUISITIONS AND DIVESTITURES	9 Months Ended
ACQUISITIONS AND DIVESTITURES	Sep. 28, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
ACQUISITIONS AND DIVESTITURES	ACQUISITIONS AND DIVESTITURES Fiscal 2023 Acquisition Noveprim Group On November 30, 2023, the Company completed the acquisition of an additional 41% equity interest of Noveprim Group (Noveprim), a leading supplier of non-human primates (NHPs) located in Mauritius, resulting in a 90% controlling interest. The Company had previously acquired a 49% equity interest in 2022 for $90.0 million plus additional contingent payments up to $5.0 million based on future performance. The total consideration allocable to the Noveprim acquisition is $392.4 million, which includes $144.6 million additional cash paid for the 41% equity interest, elimination of historical activity and intercompany balances of $209.5 million which includes a remeasurement gain on the 49% equity investment of $113.0 million, contingent consideration of $33.3 million, deferred purchase price of $12.0 million payable from 2024 through 2027, offset by estimated post-closing adjustments for working capital of $7.0 million. The purchase price reflected an agreement with seller on working capital and debt, which was adjusted from $13.8 million to $7.0 million during the nine months ended September 28, 2024. As a result of measurement period adjustments to the purchase price, goodwill and remeasurement gains on the previous 49% equity investment for the nine months ended September 28, 2024, were increased by $17.6 million and $9.8 million, respectively. Remeasurement gains are recorded in Other income (expense), net, within the unaudited condensed consolidated statements of income. The contingent consideration fair value is estimated using a Monte Carlo Simulation model and the maximum contingent contractual payments are up to $55.0 million based on future performance and milestone achievements in fiscal years 2023 through 2025. The Company has the call option right to purchase the remaining 10% equity interest up until one month after the sixth anniversary of closing the 41% equity interest. On the first anniversary of the expiration of the call option, a 12-month put option will be triggered giving the seller the right to require the Company to acquire the remaining shares of the seller. The redemption price for the call/put is fixed and ranges from $47.0 million to $54.0 million depending on when exercised. The noncontrolling interest is classified as a redeemable noncontrolling interest in the mezzanine section of the unaudited condensed consolidated balance sheets. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment for NHPs vertically integrated into the DSA supply chain and the RMS reportable segment for those NHPs sold to third party customers. The Company incurred transaction and integration costs in connection with the acquisition of $0.3 million and $0.7 million for the three months ended September 28, 2024 and September 30, 2023, respectively, which was primarily included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income. The Company incurred transaction and integration costs in connection with the acquisition of $1.2 million and $2.9 million for the nine months ended September 28, 2024 and September 30, 2023, respectively, which was primarily included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income. SAMDI Tech, Inc. On January 27, 2023, the Company acquired SAMDI Tech, Inc., (SAMDI), a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research. The acquisition of SAMDI will provide clients with seamless access to the premier, label-free HTS MS platform and create a comprehensive, library of drug discovery solutions. The purchase price of SAMDI was $62.8 million, net of $0.4 million in cash, inclusive of a 20% strategic equity interest previously owned by the Company of $12.6 million. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment. No significant transaction and integration costs were incurred with the acquisition for the three and nine months ended September 28, 2024. The Company incurred transaction and integration costs in connection with the acquisition of $0.5 million and $0.8 million for the three and nine months ended September 30, 2023, respectively, which was primarily included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income. Purchase price information The purchase price allocation was as follows: Noveprim Group (1) SAMDI Tech, Inc. November 30, 2023 January 27, 2023 (in thousands) Trade receivables $ 1,308 $ 513 Inventories 66,500 — Other current assets (excluding cash) 3,261 75 Property, plant and equipment 36,154 593 Operating lease right-of-use asset, net 104 — Goodwill (2) 190,024 37,129 Definite-lived intangible assets 9,500 33,070 Other long-term assets (3) 167,907 6 Deferred revenue — (43) Other current liabilities (16,268) (351) Operating lease right-of-use liabilities (Long-term) (97) — Deferred tax liabilities (12,984) (8,191) Other long-term liabilities (7,579) — Redeemable noncontrolling interest (4) (45,426) — Total purchase price allocation $ 392,404 $ 62,801 (1) Purchase price allocation is preliminary and subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts, obligations, and finalization of any working capital adjustments. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. (2) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses or synergies to be realized from acquiring an internal supplier servicing the DSA business and the assembled workforce of the acquirees, thus is not deductible for tax purposes. (3) Other long-term assets acquired from the Noveprim acquisition include $167.8 million of biological assets, which will be amortized over an estimated eight (4) Refer to Note 12 – Equity and Noncontrolling Interests for further a description of the 10% noncontrolling interest fair value. The definite-lived intangible assets acquired were as follows: Noveprim Group SAMDI Tech, Inc. Definite-Lived Intangible Assets (in thousands) Client relationships $ — $ 23,400 Other intangible assets 9,500 9,670 Total definite-lived intangible assets $ 9,500 $ 33,070 Weighted Average Amortization Life (in years) Client relationships — 15 Other intangible assets 7 7 Total definite-lived intangible assets 7 12

REVENUE FROM CONTRACTS WITH CUS

REVENUE FROM CONTRACTS WITH CUSTOMERS	9 Months Ended
REVENUE FROM CONTRACTS WITH CUSTOMERS	Sep. 28, 2024
Revenue from Contract with Customer [Abstract]
REVENUE FROM CONTRACTS WITH CUSTOMERS	REVENUE FROM CONTRACTS WITH CUSTOMERS Disaggregation of Revenue The following table disaggregates the Company’s revenue by reportable segment and timing of transfer of products or services: Three Months Ended Nine Months Ended September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 (in thousands) Timing of Revenue Recognition: RMS Services and products transferred over time $ 93,446 $ 94,883 $ 285,794 $ 282,980 Services and products transferred at a point in time 104,378 91,965 339,326 313,582 Total RMS revenue 197,824 186,848 625,120 596,562 DSA Services and products transferred over time 613,388 663,128 1,844,298 1,987,617 Services and products transferred at a point in time 1,672 900 3,633 2,221 Total DSA revenue 615,060 664,028 1,847,931 1,989,838 Manufacturing Services and products transferred over time 107,284 94,446 311,823 280,992 Services and products transferred at a point in time 89,595 81,301 262,566 248,541 Total Manufacturing revenue 196,879 175,747 574,389 529,533 Total revenue $ 1,009,763 $ 1,026,623 $ 3,047,440 $ 3,115,933 Contract Balances from Contracts with Customers The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers: September 28, 2024 December 30, 2023 (in thousands) Assets from contracts with customers Client receivables $ 557,761 $ 578,077 Unbilled revenue 220,323 228,020 Total 778,084 806,097 Less: Allowance for credit losses (23,877) (25,722) Trade receivables and contract assets, net $ 754,207 $ 780,375 Liabilities from contracts with customers Current deferred revenue $ 251,968 $ 241,820 Long-term deferred revenue (included in Other long-term liabilities) 34,915 30,919 Customer contract deposits (included in Other current liabilities) 99,455 85,554 Approximately 90% of unbilled revenue as of December 30, 2023, which was $228 million, was billed during the nine months ended September 28, 2024. Approximately 90% of unbilled revenue as of December 31, 2022, which was $204 million, was billed during the nine months ended September 30, 2023. Approximately 80% of contract liabilities as of December 30, 2023, which was $273 million, were recognized as revenue during the nine months ended September 28, 2024. Approximately 80% of contract liabilities as of December 31, 2022, which was $290 million, were recognized as revenue during the nine months ended September 30, 2023. When the Company does not have the unconditional right to advanced billings, both advanced client payments and unpaid advanced client billings are excluded from deferred revenue, with the advanced billings also being excluded from client receivables. The Company excluded approximately $36 million and $41 million of unpaid advanced client billings from both client receivables and deferred revenue in the accompanying unaudited condensed consolidated balance sheets as of September 28, 2024 and December 30, 2023, respectively. Allowance for Credit Losses The following is a summary of the activity of the Company’s allowance for credit losses: Nine Months Ended September 28, 2024 September 30, 2023 (in thousands) Beginning balance $ 25,722 $ 11,278 Provisions 8,223 11,030 Reductions (10,068) (1,121) Ending balance $ 23,877 $ 21,187 Net provision expenses were $7.2 million and $10.2 million during the nine months ended September 28, 2024 and September 30, 2023, respectively and include recoveries of balances previously written off, which are excluded from the table above. Transaction Price Allocated to Future Performance Obligations The Company discloses the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of September 28, 2024. Excluded from the disclosure is the value of unsatisfied performance obligations for contracts with an original expected length of one year or less, contracts for which revenue is recognized at the amount to which the Company has the right to invoice for services performed, and service revenue recognized in accordance with ASC 842, “Leases”. The aggregate amount of transaction price allocated to the remaining performance obligations for all open customer contracts as of September 28, 2024 was $803.5 million. The Company will recognize revenues for these performance obligations as they are satisfied, approximately 50% of which is expected to occur within the next twelve months and the remainder recognized thereafter during the remaining contract term. Other Performance Obligation s As part of the Company’s service offerings, the Company has identified performance obligations related to leasing Company owned assets. In certain arrangements, customers obtain substantially all of the economic benefits of the identified assets, which may include manufacturing suites and related equipment, and have the right to direct the assets’ use over the term of the contract. The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year. Three Months Ended Nine Months Ended September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 Affected Line Item in the Unaudited Condensed Consolidated Statements of Income (in thousands) Lease revenue $ 16,622 $ 22,254 $ 54,312 $ 70,235 Service revenue

SEGMENT AND GEOGRAPHIC INFORMAT

SEGMENT AND GEOGRAPHIC INFORMATION	9 Months Ended
SEGMENT AND GEOGRAPHIC INFORMATION	Sep. 28, 2024
Segment Reporting [Abstract]
SEGMENT AND GEOGRAPHIC INFORMATION	SEGMENT AND GEOGRAPHIC INFORMATION The Company operates in three reportable segments, RMS, DSA and Manufacturing. Asset information on a reportable segment basis is not disclosed as this information is not separately identified and internally reported to the Company’s Chief Operating Decision Maker (CODM). The following table presents the results of operations by reportable segment: Three Months Ended Nine Months Ended September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 (in thousands) RMS Revenue $ 197,824 $ 186,848 $ 625,120 $ 596,562 Cost of revenue (excluding amortization of intangible assets) 137,906 126,640 421,773 381,332 Selling, general and administrative 26,453 26,483 84,943 81,194 Amortization of intangible assets 5,921 5,399 17,763 16,383 Operating income $ 27,544 $ 28,326 $ 100,641 $ 117,653 DSA Revenue $ 615,060 $ 664,028 $ 1,847,931 $ 1,989,838 Cost of revenue (excluding amortization of intangible assets) 409,684 436,174 1,246,560 1,268,248 Selling, general and administrative 63,260 63,369 174,598 189,076 Amortization of intangible assets 15,680 17,666 47,122 52,726 Operating income $ 126,436 $ 146,819 $ 379,651 $ 479,788 Manufacturing Revenue $ 196,879 $ 175,747 $ 574,389 $ 529,533 Cost of revenue (excluding amortization of intangible assets) 113,152 101,968 331,530 327,882 Selling, general and administrative 32,737 36,338 99,397 114,556 Amortization of intangible assets 10,802 11,166 32,363 34,311 Operating income $ 40,188 $ 26,275 $ 111,099 $ 52,784 Unallocated Corporate Selling, general and administrative $ 76,763 $ 49,918 $ 196,357 $ 165,886 Operating income (1) $ (76,763) $ (49,918) $ (196,357) $ (165,886) Consolidated Revenue $ 1,009,763 $ 1,026,623 $ 3,047,440 $ 3,115,933 Cost of revenue (excluding amortization of intangible assets) 660,742 664,783 1,999,863 1,977,462 Selling, general and administrative 199,213 176,109 555,295 550,713 Amortization of intangible assets 32,403 34,229 97,248 103,419 Operating income $ 117,405 $ 151,502 $ 395,034 $ 484,339 (1) Operating income for unallocated corporate consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations. Capital expenditures and depreciation and amortization (related to both intangible assets and certain assets acquired in business combinations) by reportable segment are as follows: RMS DSA Manufacturing Unallocated Corporate Consolidated (in thousands) Capital Expenditures Three Months Ended: September 28, 2024 $ 7,186 $ 22,773 $ 8,735 $ 27 $ 38,721 September 30, 2023 9,192 41,967 14,349 439 65,947 Nine Months Ended: September 28, 2024 $ 36,543 $ 91,176 $ 28,180 $ 1,452 $ 157,351 September 30, 2023 35,769 155,477 46,949 2,010 240,205 Depreciation and amortization Three Months Ended: September 28, 2024 $ 18,389 $ 47,751 $ 20,298 $ 1,760 $ 88,198 September 30, 2023 13,872 44,088 20,070 840 78,870 Nine Months Ended: September 28, 2024 $ 53,050 $ 141,269 $ 60,176 $ 5,142 $ 259,637 September 30, 2023 41,310 129,662 59,677 2,961 233,610 Revenue represents sales originating in entities physically located in the identified geographic area. Revenue by geographic area is as follows: U.S. Europe Canada Asia Pacific Other (1) Consolidated (in thousands) Three Months Ended: September 28, 2024 $ 559,277 $ 267,123 $ 127,088 $ 45,009 $ 11,266 $ 1,009,763 September 30, 2023 590,316 264,787 129,023 40,233 2,264 1,026,623 Nine Months Ended: September 28, 2024 $ 1,693,021 $ 814,819 $ 362,733 $ 141,168 $ 35,699 $ 3,047,440 September 30, 2023 1,802,532 805,466 357,276 142,910 7,749 3,115,933 (1) The Other category represents operations located in Brazil, Israel, and Mauritius. Long-lived assets consist of property, plant, and equipment, net. Long-lived assets by geographic area are as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) Long-lived assets September 28, 2024 $ 953,412 $ 425,967 $ 152,980 $ 70,816 $ 36,803 $ 1,639,978 December 30, 2023 964,176 407,375 157,483 74,605 36,102 1,639,741

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	9 Months Ended
SUPPLEMENTAL CASH FLOW INFORMATION	Sep. 28, 2024
Supplemental Cash Flow Information [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION Nine Months Ended September 28, 2024 September 30, 2023 (in thousands) Cash paid for income taxes $ 94,609 $ 75,783 Cash paid for interest 98,572 106,014 Non-cash investing activities: Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities $ 32,764 $ 41,526 Assets acquired under finance leases 3,159 154 Cash, cash equivalents and restricted cash is included in the accompanying unaudited condensed consolidated balance sheets as follows: September 28, 2024 September 30, 2023 (in thousands) Supplemental cash flow information: Cash and cash equivalents $ 210,171 $ 157,174 Restricted cash included in Other current assets 323 6,586 Restricted cash included in Other assets 1,146 1,856 Cash, cash equivalents, and restricted cash, end of period $ 211,640 $ 165,616

INVENTORY

INVENTORY	9 Months Ended
INVENTORY	Sep. 28, 2024
Inventory Disclosure [Abstract]
INVENTORY	INVENTORY Inventories The composition of inventories is as follows: September 28, 2024 December 30, 2023 (in thousands) Raw materials and supplies $ 45,264 $ 42,296 Work in process 46,976 59,727 Finished products 243,960 278,236 Inventories $ 336,200 $ 380,259

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	9 Months Ended
PROPERTY, PLANT AND EQUIPMENT, NET	Sep. 28, 2024
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	PROPERTY, PLANT AND EQUIPMENT, NET The composition of property, plant and equipment, net is as follows: September 28, 2024 December 30, 2023 (in thousands) Land $ 79,670 $ 79,546 Buildings (1) 1,097,064 1,053,915 Machinery and equipment (1) 1,040,195 984,867 Leasehold improvements 404,442 366,556 Furniture and fixtures 32,640 31,284 Computer hardware and software (1) 265,392 254,413 Vehicles (1) 7,502 6,746 Construction in progress 176,541 197,723 Total 3,103,446 2,975,050 Less: Accumulated depreciation (1,463,468) (1,335,309) Property, plant and equipment, net $ 1,639,978 $ 1,639,741 (1) These balances include assets under finance leases.

VENTURE CAPITAL AND STRATEGIC E

VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS	9 Months Ended
VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS	Sep. 28, 2024
Equity Method Investments and Joint Ventures [Abstract]
VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS	VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS Venture capital investments are summarized below: Nine Months Ended September 28, 2024 September 30, 2023 (in thousands) Beginning balance $ 121,158 $ 129,012 Capital contributions 16,205 12,056 Distributions (20,324) (12,972) Gains (losses) 8,439 (14,258) Foreign currency translation 466 260 Ending balance $ 125,944 $ 114,098 The Company also invests, with minority positions, directly in equity of predominantly privately held companies. Strategic investments are summarized below: Nine Months Ended September 28, 2024 September 30, 2023 (in thousands) Beginning balance $ 122,653 $ 182,590 Purchase of investments 2,140 21,489 Distributions — (7,493) Gain (loss) (9,430) 5,012 Reduction for acquisition of entity (1) — (12,635) Other investment activity (5,540) — Foreign currency translation 220 (1,214) Ending balance $ 110,043 $ 187,749 (1) Refer to Note 2 – Acquisitions and Divestitures for further discussion on the acquisition of SAMDI.

FAIR VALUE

FAIR VALUE	9 Months Ended
FAIR VALUE	Sep. 28, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE Assets and liabilities measured at fair value on a recurring basis are summarized below: September 28, 2024 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ — $ 30 $ — $ 30 Interest rate swap — 278 — 278 Other assets: Life insurance policies — 47,734 — 47,734 Total assets measured at fair value $ — $ 48,042 $ — $ 48,042 Other long-term liabilities measured at fair value: Contingent consideration $ — $ — $ 39,893 $ 39,893 Total liabilities measured at fair value $ — $ — $ 39,893 $ 39,893 The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the nine months ended September 28, 2024, there were no transfers between levels. December 30, 2023 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ — $ 29 $ — $ 29 Other assets: Life insurance policies — 40,912 — 40,912 Interest rate swap — 966 — 966 Total assets measured at fair value $ — $ 41,907 $ — $ 41,907 Other long-term liabilities measured at fair value Contingent consideration $ — $ — $ 33,265 $ 33,265 Total liabilities measured at fair value $ — $ — $ 33,265 $ 33,265 During the year ended December 30, 2023, there were no transfers between levels. Contingent Consideration The following table provides a rollforward of the contingent consideration related to the Company’s acquisitions. Nine Months Ended September 28, 2024 September 30, 2023 (in thousands) Beginning balance $ 33,265 $ 13,431 Payments — (15,130) Total gains or losses (realized/unrealized): Adjustment of previously recorded contingent liability 6,628 1,810 Foreign currency translation — (111) Ending balance $ 39,893 $ — The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, which incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The unobservable inputs used in the fair value measurements include the probabilities of successful achievement of certain financial targets, forecasted results or targets, volatility, and discount rates. The remaining maximum potential payments are approximately $55.0 million, of which the value accrued as of September 28, 2024 is $39.9 million as the probability of achieving the maximum target is estimated to be 73%. The volatility and weighted average cost of capital is approximately 5% and 8%, respectively. Increases or decreases in these assumptions may result in a higher or lower fair value measurement, respectively. Cash Flow Hedge The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. The Company had an interest rate swap with a notional amount of $500 million maturing November 2, 2024 to manage interest rate fluctuation related to floating rate borrowings under the Credit Facility, at a fixed rate of 4.65%. Debt Instruments The book value of the Company’s revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2 within the fair value hierarchy. The book value of the Company’s Senior Notes are fixed rate obligations carried at amortized cost. Fair value is based on quoted market prices as well as borrowing rates available to the Company. As the fair value is based on significant other observable outputs, it is deemed to be Level 2 within the fair value hierarchy. The book value and fair value of the Company’s Senior Notes is summarized below: September 28, 2024 December 30, 2023 Book Value Fair Value Book Value Fair Value (in thousands) 4.25% Senior Notes due 2028 $ 500,000 $ 484,350 $ 500,000 $ 478,100 3.75% Senior Notes due 2029 500,000 470,100 500,000 458,100 4.00% Senior Notes due 2031 500,000 459,350 500,000 449,350

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	9 Months Ended
GOODWILL AND INTANGIBLE ASSETS	Sep. 28, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Goodwill The following table provides a rollforward of the Company’s goodwill: RMS DSA (1) Manufacturing Total (in thousands) December 30, 2023 $ 497,474 $ 1,662,434 $ 935,137 $ 3,095,045 Acquisitions — 17,675 — 17,675 Foreign exchange 203 (4,480) 16,149 11,872 September 28, 2024 $ 497,677 $ 1,675,629 $ 951,286 $ 3,124,592 (1) DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010. The increase in goodwill during the nine months ended September 28, 2024 is related to measurement period adjustments related to the acquisition of Noveprim in the DSA reportable segment and foreign exchange in Manufacturing. During the third quarter ended September 28, 2024, a triggering event was identified for the Discovery Services reporting unit (part of the DSA reportable segment). This resulted from a continuous decline in market conditions and operational challenges, ultimately resulting in a reduction of Discovery Services’ long range financial outlook. In response, management conducted a quantitative impairment test for goodwill to determine if the goodwill in the Discovery Services reporting unit was impaired. Upon completion of a quantitative impairment test, it was determined that the fair value of the reporting unit exceeded its carrying value by approximately 22%, and no impairment was recognized as of September 28, 2024. While the Discovery Services reporting unit is not currently impaired, the Company will continue to closely monitor future performance and any potential impacts on the value of the reporting unit. Intangible Assets, Net The following table displays intangible assets, net by major class: September 28, 2024 December 30, 2023 Gross Accumulated Amortization Net Gross Accumulated Amortization Net (in thousands) Client relationships $ 1,541,032 $ (808,507) $ 732,525 $ 1,528,780 $ (721,322) $ 807,458 Technology 144,241 (118,793) 25,448 142,190 (111,764) 30,426 Trademarks and trade names 12,091 (5,505) 6,586 11,878 (4,568) 7,310 Backlog 3,100 (3,100) — 3,100 (2,177) 923 Other 43,185 (29,283) 13,902 43,611 (25,677) 17,934 Intangible assets $ 1,743,649 $ (965,188) $ 778,461 $ 1,729,559 $ (865,508) $ 864,051 The decrease in intangible assets, net during the nine months ended September 28, 2024 related to normal amortization over the useful lives.

DEBT AND OTHER FINANCING ARRANG

DEBT AND OTHER FINANCING ARRANGEMENTS	9 Months Ended
DEBT AND OTHER FINANCING ARRANGEMENTS	Sep. 28, 2024
Debt Disclosure [Abstract]
DEBT AND OTHER FINANCING ARRANGEMENTS	DEBT AND OTHER FINANCING ARRANGEMENTS Long-term debt, net and finance leases consists of the following: September 28, 2024 December 30, 2023 (in thousands) Revolving facility $ 794,290 $ 1,129,243 4.25% Senior Notes due 2028 500,000 500,000 3.75% Senior Notes due 2029 500,000 500,000 4.00% Senior Notes due 2031 500,000 500,000 Other debt 16,122 9,575 Finance leases 31,116 28,550 Total debt and finance leases 2,341,528 2,667,368 Less: Current portion of long-term debt 157 3,172 Current portion of finance leases 3,043 2,398 Current portion of long-term debt and finance leases 3,200 5,570 Long-term debt and finance leases 2,338,328 2,661,798 Debt discount and debt issuance costs (11,675) (14,651) Long-term debt, net and finance leases $ 2,326,653 $ 2,647,147 As of September 28, 2024 and December 30, 2023, the weighted average interest rate on the Company’s debt was 4.59% and 4.93%, respectively. Letters of Credit

EQUITY AND NONCONTROLLING INTER

EQUITY AND NONCONTROLLING INTERESTS	9 Months Ended
EQUITY AND NONCONTROLLING INTERESTS	Sep. 28, 2024
Equity [Abstract]
EQUITY AND NONCONTROLLING INTERESTS	EQUITY AND NONCONTROLLING INTERESTS Earnings Per Share The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share: Three Months Ended Nine Months Ended September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 (in thousands) Numerator: Net income $ 70,295 $ 88,021 $ 239,038 $ 291,418 Less: Net income attributable to noncontrolling interests 638 632 2,340 3,878 Net income attributable to Charles River Laboratories International Inc. 69,657 87,389 236,698 287,540 Calculation of net income per share attributable to Charles River Laboratories International Inc. common shareholders Net income attributable to Charles River Laboratories International Inc. $ 69,657 $ 87,389 $ 236,698 $ 287,540 Less: Adjustment of redeemable noncontrolling interest (1) 379 — 1,081 — Less: Incremental dividends attributable to noncontrolling interest holders (2) 599 — 9,621 — Net income available to Charles River Laboratories International Inc. common shareholders $ 68,679 $ 87,389 $ 225,996 $ 287,540 Denominator: Weighted-average shares outstanding - Basic 51,394 51,283 51,461 51,199 Effect of dilutive securities: Stock options, restricted stock units and performance share units 189 324 252 294 Weighted-average shares outstanding - Diluted 51,583 51,607 51,713 51,493 Anti-dilutive common stock equivalents (3) 746 588 505 514 (1) Represents adjustments of redeemable noncontrolling interest that impact retained earnings. (2) Represents incremental declared and undeclared dividends attributable to Noveprim noncontrolling interest holders who are entitled to preferential dividends for fiscal year 2024. (3) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect. Treasury Shares On August 2, 2024, the Company’s Board of Directors approved a stock repurchase authorization of $1.0 billion . This authorization fully replaces a prior stock repurchase authorization of $1.3 billion that had $129.1 million remaining when it was terminated. During the three and nine months ended September 28, 2024, the Company repurchased 0.5 million shares of common stock for $100.7 million under the new stock repurchase program. As of September 28, 2024, the Company had $899.3 million remaining on the current authorized stock repurchase program. The Company’s stock-based compensation plans permit the netting of common stock upon vesting of RSUs and PSUs in order to satisfy individual statutory tax withholding requirements. The Company acquired shares of approximately 0.1 million in the nine months ended September 28, 2024 and nine months ended September 30, 2023, for $18.4 million and $24.0 million, respectively, from such netting. Accumulated Other Comprehensive Income (Loss) Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows: Foreign Currency Translation Adjustment Pension and Other Post-Retirement Benefit Plans Net Unrealized (Loss) Gain on Cash Flow Hedge Total (in thousands) December 30, 2023 $ (149,999) $ (47,167) $ 739 $ (196,427) Other comprehensive income (loss) before reclassifications 4,054 1,038 (688) 4,404 Net current period other comprehensive income (loss) 4,054 1,038 (688) 4,404 Income tax expense (benefit) 757 256 (165) 848 September 28, 2024 $ (146,702) $ (46,385) $ 216 $ (192,871) Redeemable Noncontrolling Interests Through September 28, 2024, the Company holds several redeemable noncontrolling interests. Since the Company has the right to purchase, and the noncontrolling interest holders have the right to require the Company to purchase the remaining interest, which represents a derivative embedded within the equity instrument, the noncontrolling interest is classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities. The redeemable noncontrolling interests are measured at the greater of (i) the redemption amount or (ii) the historical value resulting from the original acquisition date fair value, increased or decreased for the noncontrolling interest’s share of net income (loss), equity capital contributions and distributions. The fair value of the redeemable noncontrolling interest is determined using the income approach, with key assumptions being projected cash flows and discount rates based on market participant’s weighted average cost of capital. To the extent redemption value exceeds carrying value, adjustments are recorded to additional paid-in capital, with any cumulative excess of redemption value over fair value recorded in retained earnings, which impacts net income available to common shareholders used in the calculation of earnings per common share. Noveprim The Company holds a 90% ownership interest in Noveprim. The Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 10% equity interest at a fixed redemption value that ranges from $47.0 million to $54.0 million depending on when exercised. The Company has the call option right to purchase the remaining 10% equity up until one month after the sixth anniversary of closing the 41% equity stake (December 2029). On the first anniversary of the expiration of the call option (December 2030), a 12-month put option will be triggered giving the seller the right to require the Company to acquire the remaining shares of the seller for $54.0 million. Additionally, during fiscal year 2024 the 10% noncontrolling interest holders have and may continue to receive a dividend disproportionate to their equity ownership, of which the fair value of $8.0 million as of the acquisition date was recorded within the redeemable noncontrolling interest. Through September 28, 2024, incremental dividends based on Noveprim statutory net income attributed to the redeemable noncontrolling interest holders of $9.6 million reduced net income available to common shareholders used in the calculation of earnings per common share. The redemption value is accreted to the put purchase price of $54.0 million using the interest method through December 2030. As of September 28, 2024, the redemption value of $40.6 million exceeded both the carrying value and fair value, resulting in both an adjustment to additional paid in capital of $7.2 million and an adjustment to retained earnings of $1.1 million, respectively, for the nine months ended September 28, 2024 . Other redeemable noncontrolling interest In 2019, the Company acquired an 80% equity interest in a subsidiary, which included a 20% redeemable noncontrolling interest. In June 2022, the Company purchased an additional 10% interest in the subsidiary for $15.0 million, resulting in a remaining noncontrolling interest of 10%. Beginning in 2024, the Company had the right to purchase, and the noncontrolling interest holders had the right to sell, the remaining 10% equity interest at its appraised value. The redemption value was measured at the greater of the appraised value or a predetermined floor. The amount that the Company could be required to pay to purchase the remaining 10% equity interest was not limited. As of March 30, 2024, the redemption value of $12.0 million exceeded the carrying value, resulting in an adjustment to additional paid in capital of $2.8 million. During the second quarter of fiscal 2024, the Company acquired the remaining 10% for $12.0 million. Vital River The Company held a 92% ownership interest in Vital River, a commercial provider of research models and related services in China as of December 31, 2022 . The Company had the right to purchase, and the noncontrolling interest holders had the right to sell, the remaining 8% equity interest at a contractually defined redemption value, subject to a redemption floor. The amount that the Company could be required to pay to purchase the remaining 8% equity interest was not limited. During 2023, the Company acquired the remaining 8% and paid $4.8 million of the total $24.4 million due. The remaining purchase price payable was included in Accrued liabilities within the Company’s unaudited condensed consolidated balance sheet as of September 28, 2024 and December 30, 2023 and is expected to be paid during fiscal year 2024. Nonredeemable Noncontrolling Interest

INCOME TAXES

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 28, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rates for the three months ended September 28, 2024 and September 30, 2023 were 23.0% and 22.0%, respectively. The increase in the effective tax rate for the three months ended September 28, 2024 compared to the corresponding prior year period was primarily attributable to the deferred tax impact of tax law changes enacted during the three months ended September 28, 2024, offset by jurisdictional earnings mix. The Company’s effective tax rates for the nine months ended September 28, 2024 and September 30, 2023 were 22.9% and 21.8%, respectively. The increase in the effective tax rate for the nine months ended September 28, 2024 compared to the same prior year period is primarily attributable the same reason as above, as well as decreased tax benefit from stock-based compensation deductions in nine months ended September 28, 2024. For the three months ended September 28, 2024, the Company’s unrecognized tax benefits increased by $1.2 million to $25.2 million, primarily due to increases in research and development tax credit reserves, as well as unfavorable foreign exchange movement. For the three months ended September 28, 2024, the amount of unrecognized income tax benefits that would impact the effective tax rate increased by $1.0 million to $22.1 million for the same reasons discussed above. The accrued interest on unrecognized tax benefits was $1.8 million as of September 28, 2024. The Company estimates that it is reasonably possible that the unrecognized tax benefits will decrease by approximately $5.1 million over the next twelve-month period, primarily due to audit settlements and expiring statutes of limitations. The Company’s prepaid and accrued tax positions are as follows: September 28, 2024 December 30, 2023 Affected Line Item in the Unaudited Condensed Consolidated Balance Sheets (in thousands) Prepaid income tax $ 82,153 $ 59,715 Other current assets Accrued income taxes 39,673 38,819 Other current liabilities The Company conducts business in a number of tax jurisdictions. As a result, it is subject to tax audits on a regular basis including, but not limited to, such major jurisdictions as the U.S., the U.K., China, France, Germany, and Canada. With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 2020. The Company and certain of its subsidiaries have ongoing tax controversies in the U.S., Canada, and India. The Company does not anticipate resolution of these audits will have a material impact on its unaudited condensed consolidated financial statements.

RESTRUCTURING AND ASSET IMPAIRM

RESTRUCTURING AND ASSET IMPAIRMENTS	9 Months Ended
RESTRUCTURING AND ASSET IMPAIRMENTS	Sep. 28, 2024
Restructuring and Related Activities [Abstract]
RESTRUCTURING AND ASSET IMPAIRMENTS	RESTRUCTURING AND ASSET IMPAIRMENTS The Company has undertaken restructuring actions impacting the reportable segments at various locations across North America, Europe and Asia. This includes workforce right-sizing actions resulting in severance and transition costs; and costs related to the consolidation of facilities resulting in asset impairment, accelerated depreciation charges, and certain other costs. Generally, these actions are in response to recent macroeconomic impacts on the Company. During fiscal year 2023, the Company began to take restructuring actions as a result of these emerging business trends. The Company incurred restructuring charges of $30.6 million and $65.6 million during the three and nine months ended September 28, 2024, respectively and approximately $95 million since the beginning of fiscal year 2023 through September 28, 2024. The following table presents restructuring costs by reportable segment: Three Months Ended Nine Months Ended September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 (in thousands) RMS $ 4,965 $ 965 $ 22,580 $ 965 DSA 13,866 13,220 24,123 13,218 Manufacturing 5,372 975 9,660 7,162 Unallocated corporate 6,443 — 9,237 — Total $ 30,646 $ 15,160 $ 65,600 $ 21,345 The following table presents restructuring costs as included within the Company’s unaudited condensed consolidated statements of income: September 28, 2024 September 30, 2023 Severance and Transition Costs Asset Impairments and Other Costs Total Severance and Transition Costs Asset Impairments and Other Costs Total (in thousands) Three Months Ended Cost of services provided (excluding amortization of intangible assets) $ 12,830 $ 3,482 $ 16,312 $ 2,160 $ 11,418 $ 13,578 Cost of products sold (excluding amortization of intangible assets) 1,783 650 2,433 480 174 654 Selling, general and administrative 11,923 (22) 11,901 937 (9) 928 Total restructuring costs $ 26,536 $ 4,110 $ 30,646 $ 3,577 $ 11,583 $ 15,160 Nine Months Ended Cost of services provided (excluding amortization of intangible assets) $ 20,510 $ 6,516 $ 27,026 $ 5,088 $ 11,418 $ 16,506 Cost of products sold (excluding amortization of intangible assets) 2,530 11,134 13,664 534 2,920 3,454 Selling, general and administrative 18,430 6,480 24,910 1,386 (1) 1,385 Total restructuring costs $ 41,470 $ 24,130 $ 65,600 $ 7,008 $ 14,337 $ 21,345 Rollforward of Restructuring Activities The following table provides a rollforward for the Company’s accrued restructuring costs related to all restructuring activities: Severance and Transition Costs Asset Impairments Other Costs Total (in thousands) Nine Months Ended September 28, 2024 Beginning balance $ 4,175 $ — $ 875 $ 5,050 Expense 41,470 15,999 8,131 65,600 Payments / utilization (17,920) — (6,762) (24,682) Other non-cash adjustments — (15,999) (1,369) (17,368) Foreign currency adjustments 57 — — 57 Ending Balance $ 27,782 $ — $ 875 $ 28,657 Nine Months Ended September 30, 2023 Beginning balance $ 356 $ — $ 944 $ 1,300 Expense 7,008 13,269 1,068 21,345 Payments / utilization (3,179) — (710) (3,889) Other non-cash adjustments — (13,269) (427) (13,696) Foreign currency adjustments (42) — — (42) Ending Balance $ 4,143 $ — $ 875 $ 5,018

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 28, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation On February 16, 2023, the Company was informed by the U.S. Department of Justice (DOJ) that in conjunction with the U.S. Fish and Wildlife Service (USFWS), it had commenced an investigation into the Company’s conduct regarding several shipments of non-human primates from Cambodia. On February 17, 2023 the Company received a grand jury subpoena requesting certain documents related to such investigation. The Company is aware of a parallel civil investigation being undertaken by the DOJ and USFWS. The Company is cooperating with the DOJ and the USFWS and believes that the concerns raised with respect to the Company’s conduct are without merit. The Company maintains a global supplier onboarding and oversight program incorporating risk-based due diligence, auditing, and monitoring practices to help ensure the quality of the Company’s supplier relationships and compliance with applicable U.S. and international laws and regulations, and has operated under the belief that all shipments of non-human primates it received satisfied the material requirements, documentation and related processes and procedures of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES), which guides the release of each import by USFWS. Notwithstanding the Company’s efforts and good-faith belief, in connection with the civil investigation, the Company has voluntarily suspended future shipments of non-human primates from Cambodia to the United States until such time that the Company and USFWS can agree upon and implement additional procedures to reasonably ensure that non-human primates imported from Cambodia are purpose-bred. The Company continues to care for the Cambodia-sourced non-human primates from certain shipments in the United States. The carrying value of the inventory related to these shipments was approximately $27 million as of September 28, 2024, which reflects the value of the shipments in accordance with the Company’s inventory accounting policy. On May 16, 2023, the Company received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena and additional inquiries, primarily related to the sourcing of non-human primates and related disclosures, and the Company is cooperating with these requests. The Company is not able to predict what action, if any, might be taken in the future by the DOJ, USFWS, SEC or other governmental authorities as a result of the investigations. None of the DOJ, USFWS or SEC has provided the Company with any specific timeline or indication as to when these investigations or, specific to the DOJ and USFWS, discussions regarding future processes and procedures, will be concluded or resolved. The Company cannot predict the timing, outcome or possible impact of the investigations, including without limitation any potential fines, penalties or liabilities. A putative securities class action (Securities Class Action) was filed on May 19, 2023 against the Company and a number of its current/former officers in the United States District Court for the District of Massachusetts. On August 31, 2023, the court appointed the State Teachers Retirement System of Ohio as lead plaintiff. An amended complaint was filed on November 14, 2023 that, among other things, included only James Foster, the Chief Executive Officer and David R. Smith, the former Chief Financial Officer as defendants along with the Company. The amended complaint asserts claims under §§ 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") on behalf of a putative class of purchasers of Company securities from May 5, 2020 through February 21, 2023, alleging that certain of the Company’s disclosures about its practices with respect to the importation of non-human primates made during the putative class period were materially false or misleading. On July 1, 2024, the court dismissed the complaint, denied the plaintiff’s informal request for leave to amend, and entered judgment for defendants. On July 30, 2024, the plaintiff filed a notice of appeal in the United States Court of Appeals for the First Circuit. While the Company cannot predict the final outcome of this matter, it believes the class action to be without merit and plans to vigorously defend against it. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with this matter. On November 8, 2023, a stockholder filed a derivative lawsuit in the U.S. District Court of the District of Delaware asserting claims on the Company’s behalf against the members of the Company’s Board of Directors and certain of the Company’s current/former officers (James Foster, the Chief Executive Officer; David R. Smith, the former Chief Financial Officer; and Flavia Pease, the current Chief Financial Officer). The complaint alleges that the defendants breached their fiduciary duties to the Company and its stockholders because certain of the Company’s disclosures about its practices with respect to the importation of non-human primates were materially false or misleading. The complaint also alleges that the defendants breached their fiduciary duties by causing the Company to fail to maintain adequate internal controls over securities disclosure and compliance with applicable law and by failing to comply with the company’s Code of Business Conduct and Ethics. The lawsuit is currently stayed by agreement of the parties pending further developments in the Securities Class Action pending in the United States Court of Appeals for the First Circuit. On August 2, 2024, a different stockholder filed a lawsuit in the U.S. District Court of Delaware asserting similar derivative claims on the Company’s behalf against members of the Company’s current and former Board of Directors and the same current/former officers based on similar allegations of purportedly misleading disclosures and non-compliance with legal rules and ethics standards in respect of the importation of non-human primates, as well as insider-trading claims against certain of the defendants. The lawsuit is currently stayed by agreement of the parties pending further developments in the Securities Class Action pending in the United States Court of Appeals for the First Circuit. While the Company cannot predict the outcome of these matters, it believes the derivative lawsuits to be without merit and plans to vigorously defend against them. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with these matters. Aside from the matters above, the Company believes there are no other matters pending against the Company that could have a material impact on the Company’s business, financial condition, or results of operations.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net income attributable to Charles River Laboratories International Inc.	$ 69,657	$ 87,389	$ 236,698	$ 287,540

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
Insider Trading Arrangements	Sep. 28, 2024 shares	Sep. 28, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
George Massaro [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On August 19, 2024, George Massaro, one of our directors, entered into a Rule 10b5-1 trading arrangement for the sale of up to 280 shares of common stock, in connection with the vesting of 559 RSUs in May 2025, subject to certain conditions. The arrangement’s expiration date is May 18, 2025.
Name	George Massaro
Title	director
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 19, 2024
Expiration Date	May 18, 2025
Arrangement Duration	272 days
George Massaro Trading Arrangement, Common Stock [Member] \| George Massaro [Member]
Trading Arrangements, by Individual
Aggregate Available	280	280
George Massaro Trading Arrangement, Restricted Stock Units (RSUs) [Member] \| George Massaro [Member]
Trading Arrangements, by Individual
Aggregate Available	559	559

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
BASIS OF PRESENTATION (Policies)	Sep. 28, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The year-end condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for fiscal year 2023 as filed with the SEC on February 14, 2024. Certain reclassifications of prior year amounts have been made to conform to the current year presentation. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations.
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
Newly Issued Accounting Pronouncements	Newly Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, “Improvements to Reportable Segment Disclosures (Topic 280)”. ASU 2023-07 modifies reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures on the consolidated financial statements, but does not believe there will be a material impact. In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures (Topic 740)”. ASU 2023-09 requires enhanced disclosures on income taxes paid, adds disaggregation of continuing operations before income taxes between foreign and domestic earnings and defines specific categories for the reconciliation of jurisdictional tax rate to effective tax rate. This ASU is effective for fiscal years beginning after December 15, 2024, and can be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures on the consolidated financial statements.
Consolidation	Consolidation The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its unaudited condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Redeemable noncontrolling interests, where the noncontrolling interest holders have the ability to require the Company to purchase the remaining interests, are classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities. Intercompany balances and transactions are eliminated in consolidation. The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end.
Segment Reporting	Segment Reporting The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The Company’s RMS reportable segment includes products and services offered within the Research Models, Research Model Services, and Cell Solutions. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Insourcing Solutions (IS), which provides colony management of clients’ research operations (including recruitment, training, staffing, and management services) within the clients’ facilities and utilizing the Charles River Accelerator and Development Lab (CRADL™) offering, which provides vivarium space to clients, Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models, and Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Cell Solutions, which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow. The Company’s DSA reportable segment includes Discovery Services and Safety Assessment services. The Company provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro (non-animal) and in vivo (in research models) studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO).

ACQUISITIONS AND DIVESTITURES (

ACQUISITIONS AND DIVESTITURES (Tables)	9 Months Ended
ACQUISITIONS AND DIVESTITURES (Tables)	Sep. 28, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of Purchase Price Allocation and Transaction and Integration Costs	The purchase price allocation was as follows: Noveprim Group (1) SAMDI Tech, Inc. November 30, 2023 January 27, 2023 (in thousands) Trade receivables $ 1,308 $ 513 Inventories 66,500 — Other current assets (excluding cash) 3,261 75 Property, plant and equipment 36,154 593 Operating lease right-of-use asset, net 104 — Goodwill (2) 190,024 37,129 Definite-lived intangible assets 9,500 33,070 Other long-term assets (3) 167,907 6 Deferred revenue — (43) Other current liabilities (16,268) (351) Operating lease right-of-use liabilities (Long-term) (97) — Deferred tax liabilities (12,984) (8,191) Other long-term liabilities (7,579) — Redeemable noncontrolling interest (4) (45,426) — Total purchase price allocation $ 392,404 $ 62,801 (1) Purchase price allocation is preliminary and subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts, obligations, and finalization of any working capital adjustments. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. (2) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses or synergies to be realized from acquiring an internal supplier servicing the DSA business and the assembled workforce of the acquirees, thus is not deductible for tax purposes. (3) Other long-term assets acquired from the Noveprim acquisition include $167.8 million of biological assets, which will be amortized over an estimated eight (4) Refer to Note 12 – Equity and Noncontrolling Interests for further a description of the 10% noncontrolling interest fair value.
Schedule of Definite-Lived Intangible Assets Acquired as Part of Business Combination	The definite-lived intangible assets acquired were as follows: Noveprim Group SAMDI Tech, Inc. Definite-Lived Intangible Assets (in thousands) Client relationships $ — $ 23,400 Other intangible assets 9,500 9,670 Total definite-lived intangible assets $ 9,500 $ 33,070 Weighted Average Amortization Life (in years) Client relationships — 15 Other intangible assets 7 7 Total definite-lived intangible assets 7 12

REVENUE FROM CONTRACTS WITH C_2

REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)	9 Months Ended
REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)	Sep. 28, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table disaggregates the Company’s revenue by reportable segment and timing of transfer of products or services: Three Months Ended Nine Months Ended September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 (in thousands) Timing of Revenue Recognition: RMS Services and products transferred over time $ 93,446 $ 94,883 $ 285,794 $ 282,980 Services and products transferred at a point in time 104,378 91,965 339,326 313,582 Total RMS revenue 197,824 186,848 625,120 596,562 DSA Services and products transferred over time 613,388 663,128 1,844,298 1,987,617 Services and products transferred at a point in time 1,672 900 3,633 2,221 Total DSA revenue 615,060 664,028 1,847,931 1,989,838 Manufacturing Services and products transferred over time 107,284 94,446 311,823 280,992 Services and products transferred at a point in time 89,595 81,301 262,566 248,541 Total Manufacturing revenue 196,879 175,747 574,389 529,533 Total revenue $ 1,009,763 $ 1,026,623 $ 3,047,440 $ 3,115,933 U.S. Europe Canada Asia Pacific Other (1) Consolidated (in thousands) Three Months Ended: September 28, 2024 $ 559,277 $ 267,123 $ 127,088 $ 45,009 $ 11,266 $ 1,009,763 September 30, 2023 590,316 264,787 129,023 40,233 2,264 1,026,623 Nine Months Ended: September 28, 2024 $ 1,693,021 $ 814,819 $ 362,733 $ 141,168 $ 35,699 $ 3,047,440 September 30, 2023 1,802,532 805,466 357,276 142,910 7,749 3,115,933 (1) The Other category represents operations located in Brazil, Israel, and Mauritius.
Schedule of Client Receivables, Contract Assets and Contract Liabilities	The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers: September 28, 2024 December 30, 2023 (in thousands) Assets from contracts with customers Client receivables $ 557,761 $ 578,077 Unbilled revenue 220,323 228,020 Total 778,084 806,097 Less: Allowance for credit losses (23,877) (25,722) Trade receivables and contract assets, net $ 754,207 $ 780,375 Liabilities from contracts with customers Current deferred revenue $ 251,968 $ 241,820 Long-term deferred revenue (included in Other long-term liabilities) 34,915 30,919 Customer contract deposits (included in Other current liabilities) 99,455 85,554 Three Months Ended Nine Months Ended September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 Affected Line Item in the Unaudited Condensed Consolidated Statements of Income (in thousands) Lease revenue $ 16,622 $ 22,254 $ 54,312 $ 70,235 Service revenue
Schedule of Allowance for Credit Losses	The following is a summary of the activity of the Company’s allowance for credit losses: Nine Months Ended September 28, 2024 September 30, 2023 (in thousands) Beginning balance $ 25,722 $ 11,278 Provisions 8,223 11,030 Reductions (10,068) (1,121) Ending balance $ 23,877 $ 21,187

SEGMENT AND GEOGRAPHIC INFORM_2

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	9 Months Ended
SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	Sep. 28, 2024
Segment Reporting [Abstract]
Schedule of Revenue and Other Financial Information by Business Segment	The following table presents the results of operations by reportable segment: Three Months Ended Nine Months Ended September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 (in thousands) RMS Revenue $ 197,824 $ 186,848 $ 625,120 $ 596,562 Cost of revenue (excluding amortization of intangible assets) 137,906 126,640 421,773 381,332 Selling, general and administrative 26,453 26,483 84,943 81,194 Amortization of intangible assets 5,921 5,399 17,763 16,383 Operating income $ 27,544 $ 28,326 $ 100,641 $ 117,653 DSA Revenue $ 615,060 $ 664,028 $ 1,847,931 $ 1,989,838 Cost of revenue (excluding amortization of intangible assets) 409,684 436,174 1,246,560 1,268,248 Selling, general and administrative 63,260 63,369 174,598 189,076 Amortization of intangible assets 15,680 17,666 47,122 52,726 Operating income $ 126,436 $ 146,819 $ 379,651 $ 479,788 Manufacturing Revenue $ 196,879 $ 175,747 $ 574,389 $ 529,533 Cost of revenue (excluding amortization of intangible assets) 113,152 101,968 331,530 327,882 Selling, general and administrative 32,737 36,338 99,397 114,556 Amortization of intangible assets 10,802 11,166 32,363 34,311 Operating income $ 40,188 $ 26,275 $ 111,099 $ 52,784 Unallocated Corporate Selling, general and administrative $ 76,763 $ 49,918 $ 196,357 $ 165,886 Operating income (1) $ (76,763) $ (49,918) $ (196,357) $ (165,886) Consolidated Revenue $ 1,009,763 $ 1,026,623 $ 3,047,440 $ 3,115,933 Cost of revenue (excluding amortization of intangible assets) 660,742 664,783 1,999,863 1,977,462 Selling, general and administrative 199,213 176,109 555,295 550,713 Amortization of intangible assets 32,403 34,229 97,248 103,419 Operating income $ 117,405 $ 151,502 $ 395,034 $ 484,339 (1) Operating income for unallocated corporate consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations. Capital expenditures and depreciation and amortization (related to both intangible assets and certain assets acquired in business combinations) by reportable segment are as follows: RMS DSA Manufacturing Unallocated Corporate Consolidated (in thousands) Capital Expenditures Three Months Ended: September 28, 2024 $ 7,186 $ 22,773 $ 8,735 $ 27 $ 38,721 September 30, 2023 9,192 41,967 14,349 439 65,947 Nine Months Ended: September 28, 2024 $ 36,543 $ 91,176 $ 28,180 $ 1,452 $ 157,351 September 30, 2023 35,769 155,477 46,949 2,010 240,205 Depreciation and amortization Three Months Ended: September 28, 2024 $ 18,389 $ 47,751 $ 20,298 $ 1,760 $ 88,198 September 30, 2023 13,872 44,088 20,070 840 78,870 Nine Months Ended: September 28, 2024 $ 53,050 $ 141,269 $ 60,176 $ 5,142 $ 259,637 September 30, 2023 41,310 129,662 59,677 2,961 233,610
Schedule of Revenue by Geographic Area	The following table disaggregates the Company’s revenue by reportable segment and timing of transfer of products or services: Three Months Ended Nine Months Ended September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 (in thousands) Timing of Revenue Recognition: RMS Services and products transferred over time $ 93,446 $ 94,883 $ 285,794 $ 282,980 Services and products transferred at a point in time 104,378 91,965 339,326 313,582 Total RMS revenue 197,824 186,848 625,120 596,562 DSA Services and products transferred over time 613,388 663,128 1,844,298 1,987,617 Services and products transferred at a point in time 1,672 900 3,633 2,221 Total DSA revenue 615,060 664,028 1,847,931 1,989,838 Manufacturing Services and products transferred over time 107,284 94,446 311,823 280,992 Services and products transferred at a point in time 89,595 81,301 262,566 248,541 Total Manufacturing revenue 196,879 175,747 574,389 529,533 Total revenue $ 1,009,763 $ 1,026,623 $ 3,047,440 $ 3,115,933 U.S. Europe Canada Asia Pacific Other (1) Consolidated (in thousands) Three Months Ended: September 28, 2024 $ 559,277 $ 267,123 $ 127,088 $ 45,009 $ 11,266 $ 1,009,763 September 30, 2023 590,316 264,787 129,023 40,233 2,264 1,026,623 Nine Months Ended: September 28, 2024 $ 1,693,021 $ 814,819 $ 362,733 $ 141,168 $ 35,699 $ 3,047,440 September 30, 2023 1,802,532 805,466 357,276 142,910 7,749 3,115,933 (1) The Other category represents operations located in Brazil, Israel, and Mauritius.
Schedule of Long-Lived Assets by Geographic Area	Long-lived assets by geographic area are as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) Long-lived assets September 28, 2024 $ 953,412 $ 425,967 $ 152,980 $ 70,816 $ 36,803 $ 1,639,978 December 30, 2023 964,176 407,375 157,483 74,605 36,102 1,639,741

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	9 Months Ended
SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	Sep. 28, 2024
Supplemental Cash Flow Information [Abstract]
Schedule of Supplemental Cash Flow Information	Nine Months Ended September 28, 2024 September 30, 2023 (in thousands) Cash paid for income taxes $ 94,609 $ 75,783 Cash paid for interest 98,572 106,014 Non-cash investing activities: Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities $ 32,764 $ 41,526 Assets acquired under finance leases 3,159 154 Cash, cash equivalents and restricted cash is included in the accompanying unaudited condensed consolidated balance sheets as follows: September 28, 2024 September 30, 2023 (in thousands) Supplemental cash flow information: Cash and cash equivalents $ 210,171 $ 157,174 Restricted cash included in Other current assets 323 6,586 Restricted cash included in Other assets 1,146 1,856 Cash, cash equivalents, and restricted cash, end of period $ 211,640 $ 165,616

INVENTORY (Tables)

INVENTORY (Tables)	9 Months Ended
INVENTORY (Tables)	Sep. 28, 2024
Inventory Disclosure [Abstract]
Schedule of Composition of Inventories	The composition of inventories is as follows: September 28, 2024 December 30, 2023 (in thousands) Raw materials and supplies $ 45,264 $ 42,296 Work in process 46,976 59,727 Finished products 243,960 278,236 Inventories $ 336,200 $ 380,259

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	9 Months Ended
PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	Sep. 28, 2024
Property, Plant and Equipment [Abstract]
Schedule of Composition of Property, Plant and Equipment, Net	The composition of property, plant and equipment, net is as follows: September 28, 2024 December 30, 2023 (in thousands) Land $ 79,670 $ 79,546 Buildings (1) 1,097,064 1,053,915 Machinery and equipment (1) 1,040,195 984,867 Leasehold improvements 404,442 366,556 Furniture and fixtures 32,640 31,284 Computer hardware and software (1) 265,392 254,413 Vehicles (1) 7,502 6,746 Construction in progress 176,541 197,723 Total 3,103,446 2,975,050 Less: Accumulated depreciation (1,463,468) (1,335,309) Property, plant and equipment, net $ 1,639,978 $ 1,639,741 (1) These balances include assets under finance leases.

VENTURE CAPITAL AND STRATEGIC_2

VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS - (Tables)	9 Months Ended
VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS - (Tables)	Sep. 28, 2024
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Equity Method Investments	Venture capital investments are summarized below: Nine Months Ended September 28, 2024 September 30, 2023 (in thousands) Beginning balance $ 121,158 $ 129,012 Capital contributions 16,205 12,056 Distributions (20,324) (12,972) Gains (losses) 8,439 (14,258) Foreign currency translation 466 260 Ending balance $ 125,944 $ 114,098 The Company also invests, with minority positions, directly in equity of predominantly privately held companies. Strategic investments are summarized below: Nine Months Ended September 28, 2024 September 30, 2023 (in thousands) Beginning balance $ 122,653 $ 182,590 Purchase of investments 2,140 21,489 Distributions — (7,493) Gain (loss) (9,430) 5,012 Reduction for acquisition of entity (1) — (12,635) Other investment activity (5,540) — Foreign currency translation 220 (1,214) Ending balance $ 110,043 $ 187,749 (1) Refer to Note 2 – Acquisitions and Divestitures for further discussion on the acquisition of SAMDI.

FAIR VALUE (Tables)

FAIR VALUE (Tables)	9 Months Ended
FAIR VALUE (Tables)	Sep. 28, 2024
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis are summarized below: September 28, 2024 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ — $ 30 $ — $ 30 Interest rate swap — 278 — 278 Other assets: Life insurance policies — 47,734 — 47,734 Total assets measured at fair value $ — $ 48,042 $ — $ 48,042 Other long-term liabilities measured at fair value: Contingent consideration $ — $ — $ 39,893 $ 39,893 Total liabilities measured at fair value $ — $ — $ 39,893 $ 39,893 December 30, 2023 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ — $ 29 $ — $ 29 Other assets: Life insurance policies — 40,912 — 40,912 Interest rate swap — 966 — 966 Total assets measured at fair value $ — $ 41,907 $ — $ 41,907 Other long-term liabilities measured at fair value Contingent consideration $ — $ — $ 33,265 $ 33,265 Total liabilities measured at fair value $ — $ — $ 33,265 $ 33,265 September 28, 2024 December 30, 2023 Book Value Fair Value Book Value Fair Value (in thousands) 4.25% Senior Notes due 2028 $ 500,000 $ 484,350 $ 500,000 $ 478,100 3.75% Senior Notes due 2029 500,000 470,100 500,000 458,100 4.00% Senior Notes due 2031 500,000 459,350 500,000 449,350
Schedule of Rollforward of Contingent Consideration Related to Previous Acquisitions	The following table provides a rollforward of the contingent consideration related to the Company’s acquisitions. Nine Months Ended September 28, 2024 September 30, 2023 (in thousands) Beginning balance $ 33,265 $ 13,431 Payments — (15,130) Total gains or losses (realized/unrealized): Adjustment of previously recorded contingent liability 6,628 1,810 Foreign currency translation — (111) Ending balance $ 39,893 $ —

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	9 Months Ended
GOODWILL AND INTANGIBLE ASSETS (Tables)	Sep. 28, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table provides a rollforward of the Company’s goodwill: RMS DSA (1) Manufacturing Total (in thousands) December 30, 2023 $ 497,474 $ 1,662,434 $ 935,137 $ 3,095,045 Acquisitions — 17,675 — 17,675 Foreign exchange 203 (4,480) 16,149 11,872 September 28, 2024 $ 497,677 $ 1,675,629 $ 951,286 $ 3,124,592 (1) DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010.
Schedule of Intangible Assets	The following table displays intangible assets, net by major class: September 28, 2024 December 30, 2023 Gross Accumulated Amortization Net Gross Accumulated Amortization Net (in thousands) Client relationships $ 1,541,032 $ (808,507) $ 732,525 $ 1,528,780 $ (721,322) $ 807,458 Technology 144,241 (118,793) 25,448 142,190 (111,764) 30,426 Trademarks and trade names 12,091 (5,505) 6,586 11,878 (4,568) 7,310 Backlog 3,100 (3,100) — 3,100 (2,177) 923 Other 43,185 (29,283) 13,902 43,611 (25,677) 17,934 Intangible assets $ 1,743,649 $ (965,188) $ 778,461 $ 1,729,559 $ (865,508) $ 864,051

DEBT AND OTHER FINANCING ARRA_2

DEBT AND OTHER FINANCING ARRANGEMENTS (Tables)	9 Months Ended
DEBT AND OTHER FINANCING ARRANGEMENTS (Tables)	Sep. 28, 2024
Debt Disclosure [Abstract]
Schedule of Long-term Debt and Finance Lease Obligations	Long-term debt, net and finance leases consists of the following: September 28, 2024 December 30, 2023 (in thousands) Revolving facility $ 794,290 $ 1,129,243 4.25% Senior Notes due 2028 500,000 500,000 3.75% Senior Notes due 2029 500,000 500,000 4.00% Senior Notes due 2031 500,000 500,000 Other debt 16,122 9,575 Finance leases 31,116 28,550 Total debt and finance leases 2,341,528 2,667,368 Less: Current portion of long-term debt 157 3,172 Current portion of finance leases 3,043 2,398 Current portion of long-term debt and finance leases 3,200 5,570 Long-term debt and finance leases 2,338,328 2,661,798 Debt discount and debt issuance costs (11,675) (14,651) Long-term debt, net and finance leases $ 2,326,653 $ 2,647,147

EQUITY AND NONCONTROLLING INT_2

EQUITY AND NONCONTROLLING INTERESTS (Tables)	9 Months Ended
EQUITY AND NONCONTROLLING INTERESTS (Tables)	Sep. 28, 2024
Equity [Abstract]
Schedule of Reconciliation of the Numerator and Denominator in the Computations of the Basic and Diluted Earnings Per Share	The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share: Three Months Ended Nine Months Ended September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 (in thousands) Numerator: Net income $ 70,295 $ 88,021 $ 239,038 $ 291,418 Less: Net income attributable to noncontrolling interests 638 632 2,340 3,878 Net income attributable to Charles River Laboratories International Inc. 69,657 87,389 236,698 287,540 Calculation of net income per share attributable to Charles River Laboratories International Inc. common shareholders Net income attributable to Charles River Laboratories International Inc. $ 69,657 $ 87,389 $ 236,698 $ 287,540 Less: Adjustment of redeemable noncontrolling interest (1) 379 — 1,081 — Less: Incremental dividends attributable to noncontrolling interest holders (2) 599 — 9,621 — Net income available to Charles River Laboratories International Inc. common shareholders $ 68,679 $ 87,389 $ 225,996 $ 287,540 Denominator: Weighted-average shares outstanding - Basic 51,394 51,283 51,461 51,199 Effect of dilutive securities: Stock options, restricted stock units and performance share units 189 324 252 294 Weighted-average shares outstanding - Diluted 51,583 51,607 51,713 51,493 Anti-dilutive common stock equivalents (3) 746 588 505 514 (1) Represents adjustments of redeemable noncontrolling interest that impact retained earnings. (2) Represents incremental declared and undeclared dividends attributable to Noveprim noncontrolling interest holders who are entitled to preferential dividends for fiscal year 2024. (3) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows: Foreign Currency Translation Adjustment Pension and Other Post-Retirement Benefit Plans Net Unrealized (Loss) Gain on Cash Flow Hedge Total (in thousands) December 30, 2023 $ (149,999) $ (47,167) $ 739 $ (196,427) Other comprehensive income (loss) before reclassifications 4,054 1,038 (688) 4,404 Net current period other comprehensive income (loss) 4,054 1,038 (688) 4,404 Income tax expense (benefit) 757 256 (165) 848 September 28, 2024 $ (146,702) $ (46,385) $ 216 $ (192,871)

INCOME TAXES (Tables)

INCOME TAXES (Tables)	9 Months Ended
INCOME TAXES (Tables)	Sep. 28, 2024
Income Tax Disclosure [Abstract]
Schedule of Prepaid and Accrued Tax Positions	The Company’s prepaid and accrued tax positions are as follows: September 28, 2024 December 30, 2023 Affected Line Item in the Unaudited Condensed Consolidated Balance Sheets (in thousands) Prepaid income tax $ 82,153 $ 59,715 Other current assets Accrued income taxes 39,673 38,819 Other current liabilities

RESTRUCTURING AND ASSET IMPAI_2

RESTRUCTURING AND ASSET IMPAIRMENTS (Tables)	9 Months Ended
RESTRUCTURING AND ASSET IMPAIRMENTS (Tables)	Sep. 28, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Costs	The following table presents restructuring costs by reportable segment: Three Months Ended Nine Months Ended September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 (in thousands) RMS $ 4,965 $ 965 $ 22,580 $ 965 DSA 13,866 13,220 24,123 13,218 Manufacturing 5,372 975 9,660 7,162 Unallocated corporate 6,443 — 9,237 — Total $ 30,646 $ 15,160 $ 65,600 $ 21,345 The following table presents restructuring costs as included within the Company’s unaudited condensed consolidated statements of income: September 28, 2024 September 30, 2023 Severance and Transition Costs Asset Impairments and Other Costs Total Severance and Transition Costs Asset Impairments and Other Costs Total (in thousands) Three Months Ended Cost of services provided (excluding amortization of intangible assets) $ 12,830 $ 3,482 $ 16,312 $ 2,160 $ 11,418 $ 13,578 Cost of products sold (excluding amortization of intangible assets) 1,783 650 2,433 480 174 654 Selling, general and administrative 11,923 (22) 11,901 937 (9) 928 Total restructuring costs $ 26,536 $ 4,110 $ 30,646 $ 3,577 $ 11,583 $ 15,160 Nine Months Ended Cost of services provided (excluding amortization of intangible assets) $ 20,510 $ 6,516 $ 27,026 $ 5,088 $ 11,418 $ 16,506 Cost of products sold (excluding amortization of intangible assets) 2,530 11,134 13,664 534 2,920 3,454 Selling, general and administrative 18,430 6,480 24,910 1,386 (1) 1,385 Total restructuring costs $ 41,470 $ 24,130 $ 65,600 $ 7,008 $ 14,337 $ 21,345
Schedule of Rollforward of Company's Severance and Retention Costs Liability	The following table provides a rollforward for the Company’s accrued restructuring costs related to all restructuring activities: Severance and Transition Costs Asset Impairments Other Costs Total (in thousands) Nine Months Ended September 28, 2024 Beginning balance $ 4,175 $ — $ 875 $ 5,050 Expense 41,470 15,999 8,131 65,600 Payments / utilization (17,920) — (6,762) (24,682) Other non-cash adjustments — (15,999) (1,369) (17,368) Foreign currency adjustments 57 — — 57 Ending Balance $ 27,782 $ — $ 875 $ 28,657 Nine Months Ended September 30, 2023 Beginning balance $ 356 $ — $ 944 $ 1,300 Expense 7,008 13,269 1,068 21,345 Payments / utilization (3,179) — (710) (3,889) Other non-cash adjustments — (13,269) (427) (13,696) Foreign currency adjustments (42) — — (42) Ending Balance $ 4,143 $ — $ 875 $ 5,018

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details)	9 Months Ended
BASIS OF PRESENTATION (Details)	Sep. 28, 2024 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments	3

ACQUISITIONS AND DIVESTITURES -

ACQUISITIONS AND DIVESTITURES - Narrative (Details) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended	23 Months Ended
	Jan. 27, 2023	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Dec. 31, 2022	Nov. 30, 2023
Business Acquisition [Line Items]
Cash portion of consideration transferred				$ 5,479,000	$ 50,166,000
Noveprim Group
Business Acquisition [Line Items]
Percentage of voting interests acquired							41%
Equity interest acquired (as percent)							90%
Business combination, equity stake percentage						49%
Purchase of remaining equity interest of other redeemable noncontrolling interest						$ 90,000,000
Contingent liability						$ 5,000,000
Purchase price							$ 392,400,000
Additional cash paid							144,600,000
Business combination, consideration transferred, other							209,500,000
Gain in equity equal to the excess fair value of additional equity interest purchased				9,800,000			113,000,000
Contingent consideration							33,300,000
Business combination deferred purchase price							12,000,000
Adjustments for working capital/debt		$ 7,000,000		7,000,000			13,800,000
Goodwill, purchase accounting adjustments				17,600,000
Consideration contingent upon future performance							$ 55,000,000
Business combination, remaining equity to purchase (as percent)							10%
Call option term, period after sixth anniversary (in months)							1 month
Put option term, period after first anniversary (in months)							12 months
Transaction and integration costs		300,000	$ 700,000	1,200,000	2,900,000
Noveprim Group \| Minimum
Business Acquisition [Line Items]
Business combination, redemption price							$ 47,000,000
Noveprim Group \| Maximum
Business Acquisition [Line Items]
Business combination, redemption price							$ 54,000,000
SAMDI Tech, Inc.
Business Acquisition [Line Items]
Business combination, equity stake percentage	20%
Transaction and integration costs		$ 0	$ 500,000	$ 0	$ 800,000
Cash portion of consideration transferred	$ 62,800,000
Cash acquired	400,000
Value of previously owned interest in acquiree	$ 12,600,000

ACQUISITIONS AND DIVESTITURES_2

ACQUISITIONS AND DIVESTITURES - Schedule of Purchase Price Allocation and Transaction and Integration Costs (Details) - USD ($) $ in Thousands	Sep. 28, 2024	Dec. 30, 2023	Nov. 30, 2023	Jan. 27, 2023
Business Acquisition [Line Items]
Goodwill	$ 3,124,592	$ 3,095,045
Noveprim Group
Business Acquisition [Line Items]
Trade receivables			$ 1,308
Inventories			66,500
Other current assets (excluding cash)			3,261
Property, plant and equipment			36,154
Operating lease right-of-use asset, net			104
Goodwill			190,024
Definite-lived intangible assets			9,500
Other long-term assets			167,907
Deferred revenue			0
Other current liabilities			(16,268)
Operating lease right-of-use liabilities (Long-term)			(97)
Deferred tax liabilities			(12,984)
Other long-term liabilities			(7,579)
Redeemable noncontrolling interest			(45,426)
Total purchase price allocation			392,404
Biological assets			$ 167,800
Biological assets, useful life (in years)			8 years
Business combination, remaining equity to purchase (as percent)			10%
SAMDI Tech, Inc.
Business Acquisition [Line Items]
Trade receivables				$ 513
Inventories				0
Other current assets (excluding cash)				75
Property, plant and equipment				593
Operating lease right-of-use asset, net				0
Goodwill				37,129
Definite-lived intangible assets				33,070
Other long-term assets				6
Deferred revenue				(43)
Other current liabilities				(351)
Operating lease right-of-use liabilities (Long-term)				0
Deferred tax liabilities				(8,191)
Other long-term liabilities				0
Redeemable noncontrolling interest				0
Total purchase price allocation				$ 62,801

ACQUISITIONS AND DIVESTITURES_3

ACQUISITIONS AND DIVESTITURES - Schedule of Definite-Lived Intangible Assets Acquired as Part of Business Combination (Details) - USD ($) $ in Thousands	Nov. 30, 2023	Jan. 27, 2023
Noveprim Group
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 9,500
Weighted Average Amortization Life	7 years
Noveprim Group \| Client relationships
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 0
Weighted Average Amortization Life	0 years
Noveprim Group \| Other intangible assets
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 9,500
Weighted Average Amortization Life	7 years
SAMDI Tech, Inc.
Business Acquisition [Line Items]
Definite-Lived Intangible Assets		$ 33,070
Weighted Average Amortization Life		12 years
SAMDI Tech, Inc. \| Client relationships
Business Acquisition [Line Items]
Definite-Lived Intangible Assets		$ 23,400
Weighted Average Amortization Life		15 years
SAMDI Tech, Inc. \| Other intangible assets
Business Acquisition [Line Items]
Definite-Lived Intangible Assets		$ 9,670
Weighted Average Amortization Life		7 years

REVENUE FROM CONTRACTS WITH C_3

REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Percentage of unbilled revenue billed during period	90%	90%
Unbilled revenue	$ 220,323		$ 228,020	$ 204,000
Percentage of contract liabilities recognized as revenue during period	80%	80%
Contract liabilities			273,000	$ 290,000
Unpaid advanced client billings	$ 36,000		$ 41,000
Net provision expense	7,200	$ 10,200
Performance obligations expected to be satisfied	$ 803,500
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-09-29
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, percentage	50%
Performance obligations expected to be satisfied, expected timing	12 months

REVENUE FROM CONTRACTS WITH C_4

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Disaggregation of Revenues by Major Business Line (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,009,763	$ 1,026,623	$ 3,047,440	$ 3,115,933
RMS
Disaggregation of Revenue [Line Items]
Total revenue	197,824	186,848	625,120	596,562
RMS \| Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	93,446	94,883	285,794	282,980
RMS \| Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	104,378	91,965	339,326	313,582
DSA
Disaggregation of Revenue [Line Items]
Total revenue	615,060	664,028	1,847,931	1,989,838
DSA \| Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	613,388	663,128	1,844,298	1,987,617
DSA \| Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	1,672	900	3,633	2,221
Manufacturing
Disaggregation of Revenue [Line Items]
Total revenue	196,879	175,747	574,389	529,533
Manufacturing \| Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	107,284	94,446	311,823	280,992
Manufacturing \| Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	$ 89,595	$ 81,301	$ 262,566	$ 248,541

REVENUE FROM CONTRACTS WITH C_5

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Client Receivables, Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	Sep. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Client receivables	$ 557,761	$ 578,077
Unbilled revenue	220,323	228,020	$ 204,000
Total	778,084	806,097
Less: Allowance for credit losses	(23,877)	(25,722)
Trade receivables and contract assets, net	754,207	780,375
Current deferred revenue	251,968	241,820
Long-term deferred revenue (included in Other long-term liabilities)	34,915	30,919
Customer contract deposits (included in Other current liabilities)	$ 99,455	$ 85,554

REVENUE FROM CONTRACTS WITH C_6

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Allowance for Credit Losses (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 25,722	$ 11,278
Provisions	8,223	11,030
Reductions	(10,068)	(1,121)
Ending balance	$ 23,877	$ 21,187

REVENUE FROM CONTRACTS WITH C_7

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Lease Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Lease revenue	$ 16,622	$ 22,254	$ 54,312	$ 70,235

SEGMENT AND GEOGRAPHIC INFORM_3

SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue and Other Financial Information by Reportable Segment (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 28, 2024 USD ($) segment	Sep. 30, 2023 USD ($)
Segment Reporting [Abstract]
Number of reportable segments \| segment			3
Segment Reporting Information [Line Items]
Revenue	$ 1,009,763	$ 1,026,623	$ 3,047,440	$ 3,115,933
Cost of revenue (excluding amortization of intangible assets)	660,742	664,783	1,999,863	1,977,462
Selling, general and administrative	199,213	176,109	555,295	550,713
Amortization of intangible assets	32,403	34,229	97,248	103,419
Operating income	117,405	151,502	395,034	484,339
Capital Expenditures	38,721	65,947	157,351	240,205
Depreciation and amortization	88,198	78,870	259,637	233,610
Unallocated corporate
Segment Reporting Information [Line Items]
Selling, general and administrative	76,763	49,918	196,357	165,886
Operating income	(76,763)	(49,918)	(196,357)	(165,886)
Capital Expenditures	27	439	1,452	2,010
Depreciation and amortization	1,760	840	5,142	2,961
RMS
Segment Reporting Information [Line Items]
Revenue	197,824	186,848	625,120	596,562
RMS \| Operating Segments
Segment Reporting Information [Line Items]
Revenue	197,824	186,848	625,120	596,562
Cost of revenue (excluding amortization of intangible assets)	137,906	126,640	421,773	381,332
Selling, general and administrative	26,453	26,483	84,943	81,194
Amortization of intangible assets	5,921	5,399	17,763	16,383
Operating income	27,544	28,326	100,641	117,653
Capital Expenditures	7,186	9,192	36,543	35,769
Depreciation and amortization	18,389	13,872	53,050	41,310
DSA
Segment Reporting Information [Line Items]
Revenue	615,060	664,028	1,847,931	1,989,838
DSA \| Operating Segments
Segment Reporting Information [Line Items]
Revenue	615,060	664,028	1,847,931	1,989,838
Cost of revenue (excluding amortization of intangible assets)	409,684	436,174	1,246,560	1,268,248
Selling, general and administrative	63,260	63,369	174,598	189,076
Amortization of intangible assets	15,680	17,666	47,122	52,726
Operating income	126,436	146,819	379,651	479,788
Capital Expenditures	22,773	41,967	91,176	155,477
Depreciation and amortization	47,751	44,088	141,269	129,662
Manufacturing
Segment Reporting Information [Line Items]
Revenue	196,879	175,747	574,389	529,533
Manufacturing \| Operating Segments
Segment Reporting Information [Line Items]
Revenue	196,879	175,747	574,389	529,533
Cost of revenue (excluding amortization of intangible assets)	113,152	101,968	331,530	327,882
Selling, general and administrative	32,737	36,338	99,397	114,556
Amortization of intangible assets	10,802	11,166	32,363	34,311
Operating income	40,188	26,275	111,099	52,784
Capital Expenditures	8,735	14,349	28,180	46,949
Depreciation and amortization	$ 20,298	$ 20,070	$ 60,176	$ 59,677

SEGMENT AND GEOGRAPHIC INFORM_4

SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue and Long-Lived Assets by Geographic Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023
Segment Reporting Information [Line Items]
Revenue	$ 1,009,763	$ 1,026,623	$ 3,047,440	$ 3,115,933
Long-lived assets	1,639,978		1,639,978		$ 1,639,741
U.S.
Segment Reporting Information [Line Items]
Revenue	559,277	590,316	1,693,021	1,802,532
Long-lived assets	953,412		953,412		964,176
Europe
Segment Reporting Information [Line Items]
Revenue	267,123	264,787	814,819	805,466
Long-lived assets	425,967		425,967		407,375
Canada
Segment Reporting Information [Line Items]
Revenue	127,088	129,023	362,733	357,276
Long-lived assets	152,980		152,980		157,483
Asia Pacific
Segment Reporting Information [Line Items]
Revenue	45,009	40,233	141,168	142,910
Long-lived assets	70,816		70,816		74,605
Other (1)
Segment Reporting Information [Line Items]
Revenue	11,266	$ 2,264	35,699	$ 7,749
Long-lived assets	$ 36,803		$ 36,803		$ 36,102

SUPPLEMENTAL CASH FLOW INFORM_3

SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Non-Cash Investing Activities (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023
Supplemental Cash Flow Information [Abstract]
Cash paid for income taxes	$ 94,609	$ 75,783
Cash paid for interest	98,572	106,014
Non-cash investing activities:
Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities	32,764	41,526
Assets acquired under finance leases	$ 3,159	$ 154

SUPPLEMENTAL CASH FLOW INFORM_4

SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 28, 2024	Dec. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Supplemental Cash Flow Information [Abstract]
Cash and cash equivalents	$ 210,171	$ 276,771	$ 157,174
Restricted cash included in Other current assets	323		6,586
Restricted cash included in Other assets	1,146		1,856
Cash, cash equivalents, and restricted cash, end of period	$ 211,640	$ 284,480	$ 165,616	$ 241,214

INVENTORY - Narrative (Details)

INVENTORY - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
INVENTORY - Narrative (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 28, 2024
Inventory Disclosure [Abstract]
Amortization of inventory step up	$ 5.9	$ 16.5

INVENTORY - Schedule of Composi

INVENTORY - Schedule of Composition of Inventories (Details) - USD ($) $ in Thousands	Sep. 28, 2024	Dec. 30, 2023
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 45,264	$ 42,296
Work in process	46,976	59,727
Finished products	243,960	278,236
Inventories	$ 336,200	$ 380,259

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation	$ 48.5	$ 44.6	$ 141.8	$ 130.2

PROPERTY, PLANT AND EQUIPMENT_4

PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Composition of Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 28, 2024	Dec. 30, 2023
Property, Plant and Equipment [Line Items]
Total	$ 3,103,446	$ 2,975,050
Less: Accumulated depreciation	(1,463,468)	(1,335,309)
Property, plant and equipment, net	1,639,978	1,639,741
Land
Property, Plant and Equipment [Line Items]
Total	79,670	79,546
Buildings
Property, Plant and Equipment [Line Items]
Total	1,097,064	1,053,915
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total	1,040,195	984,867
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total	404,442	366,556
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total	32,640	31,284
Computer hardware and software
Property, Plant and Equipment [Line Items]
Total	265,392	254,413
Vehicles
Property, Plant and Equipment [Line Items]
Total	7,502	6,746
Construction in progress
Property, Plant and Equipment [Line Items]
Total	$ 176,541	$ 197,723

VENTURE CAPITAL AND STRATEGIC_3

VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023
Schedule of Equity Method Investments [Roll Forward]
Beginning balance	$ 243,811
Ending balance	235,987
Venture Capital Funds
Schedule of Equity Method Investments [Roll Forward]
Beginning balance	121,158	$ 129,012
Capital contributions	16,205	12,056
Distributions	(20,324)	(12,972)
Gains (losses)	8,439	(14,258)
Foreign currency translation	466	260
Ending balance	125,944	114,098
Strategic Investments
Schedule of Equity Method Investments [Roll Forward]
Beginning balance	122,653	182,590
Purchase of investments	2,140	21,489
Distributions	0	(7,493)
Gains (losses)	(9,430)	5,012
Reduction for acquisition of entity	0	(12,635)
Other investment activity	(5,540)	0
Foreign currency translation	220	(1,214)
Ending balance	$ 110,043	$ 187,749

FAIR VALUE - Schedule of Fair V

FAIR VALUE - Schedule of Fair Value of Assets and Liabilities (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Sep. 28, 2024	Dec. 30, 2023
Current assets measured at fair value:
Cash equivalents	$ 30	$ 29
Interest rate swap	278
Other assets:
Life insurance policies	47,734	40,912
Interest rate swap		966
Total assets measured at fair value	48,042	41,907
Other long-term liabilities measured at fair value:
Contingent consideration	39,893	33,265
Total liabilities measured at fair value	39,893	33,265
Level 1
Current assets measured at fair value:
Cash equivalents	0	0
Interest rate swap	0
Other assets:
Life insurance policies	0	0
Interest rate swap		0
Total assets measured at fair value	0	0
Other long-term liabilities measured at fair value:
Contingent consideration	0	0
Total liabilities measured at fair value	0	0
Level 2
Current assets measured at fair value:
Cash equivalents	30	29
Interest rate swap	278
Other assets:
Life insurance policies	47,734	40,912
Interest rate swap		966
Total assets measured at fair value	48,042	41,907
Other long-term liabilities measured at fair value:
Contingent consideration	0	0
Total liabilities measured at fair value	0	0
Level 3
Current assets measured at fair value:
Cash equivalents	0	0
Interest rate swap	0
Other assets:
Life insurance policies	0	0
Interest rate swap		0
Total assets measured at fair value	0	0
Other long-term liabilities measured at fair value:
Contingent consideration	39,893	33,265
Total liabilities measured at fair value	$ 39,893	$ 33,265

FAIR VALUE - Schedule of Contin

FAIR VALUE - Schedule of Contingent Consideration (Details) - Level 3 - Contingent Consideration - USD ($) $ in Thousands	9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 33,265	$ 13,431
Payments	0	(15,130)
Adjustment of previously recorded contingent liability	6,628	1,810
Foreign currency translation	0	(111)
Ending balance	$ 39,893	$ 0

FAIR VALUE - Narrative (Details

FAIR VALUE - Narrative (Details) - USD ($) $ in Thousands	Sep. 28, 2024	Dec. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Interest Rate Swap \| Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amount	$ 500,000
Derivative, fixed interest rate (as percent)	4.65%
Level 3 \| Contingent Consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration	$ 39,893	$ 33,265	$ 0	$ 13,431
Weighted average probability percentage of achieving maximum target	73%
Level 3 \| Contingent Consideration \| Average Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, measurement input	0.05
Level 3 \| Contingent Consideration \| Weighted Average Cost of Capital
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, measurement input	0.08
Maximum \| Level 3 \| Contingent Consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration	$ 55,000

FAIR VALUE - Schedule of Fair_2

FAIR VALUE - Schedule of Fair Value of Debt (Details) - Senior Notes - USD ($) $ in Thousands	Sep. 28, 2024	Dec. 30, 2023
4.25% Senior Notes due 2028
Debt Instrument [Line Items]
Stated interest rate (as percent)	4.25%	4.25%
4.25% Senior Notes due 2028 \| Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500,000	$ 500,000
4.25% Senior Notes due 2028 \| Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 484,350	$ 478,100
3.75% Senior Notes due 2029
Debt Instrument [Line Items]
Stated interest rate (as percent)	3.75%	3.75%
3.75% Senior Notes due 2029 \| Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500,000	$ 500,000
3.75% Senior Notes due 2029 \| Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 470,100	$ 458,100
4.00% Senior Notes due 2031
Debt Instrument [Line Items]
Stated interest rate (as percent)	4%	4%
4.00% Senior Notes due 2031 \| Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500,000	$ 500,000
4.00% Senior Notes due 2031 \| Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 459,350	$ 449,350

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Goodwill [Line Items]
Amortization of intangible assets	$ 32,403,000	$ 34,229,000	$ 97,248,000	$ 103,419,000
Discover Services Reporting Unit
Goodwill [Line Items]
Percentage of fair value in excess of carrying amount	22%		22%
Goodwill impairment	$ 0

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 28, 2024 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 3,095,045
Acquisitions	17,675
Foreign exchange	11,872
Ending balance	3,124,592
RMS
Goodwill [Roll Forward]
Beginning balance	497,474
Acquisitions	0
Foreign exchange	203
Ending balance	497,677
DSA
Goodwill [Roll Forward]
Beginning balance	1,662,434
Acquisitions	17,675
Foreign exchange	(4,480)
Ending balance	1,675,629
Goodwill, impaired, accumulated impairment loss	1,000,000
Manufacturing
Goodwill [Roll Forward]
Beginning balance	935,137
Acquisitions	0
Foreign exchange	16,149
Ending balance	$ 951,286

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 28, 2024	Dec. 30, 2023
Other intangible assets
Gross	$ 1,743,649	$ 1,729,559
Accumulated Amortization	(965,188)	(865,508)
Net	778,461	864,051
Client relationships
Other intangible assets
Gross	1,541,032	1,528,780
Accumulated Amortization	(808,507)	(721,322)
Net	732,525	807,458
Technology
Other intangible assets
Gross	144,241	142,190
Accumulated Amortization	(118,793)	(111,764)
Net	25,448	30,426
Trademarks and trade names
Other intangible assets
Gross	12,091	11,878
Accumulated Amortization	(5,505)	(4,568)
Net	6,586	7,310
Backlog
Other intangible assets
Gross	3,100	3,100
Accumulated Amortization	(3,100)	(2,177)
Net	0	923
Other
Other intangible assets
Gross	43,185	43,611
Accumulated Amortization	(29,283)	(25,677)
Net	$ 13,902	$ 17,934

DEBT AND OTHER FINANCING ARRA_3

DEBT AND OTHER FINANCING ARRANGEMENTS - Narrative (Details) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 30, 2023
Debt Instrument [Line Items]
Weighted average interest rate (as percent)	4.59%	4.93%
Letter of Credit
Debt Instrument [Line Items]
Letters of credit outstanding	$ 21.2	$ 21.6

DEBT AND OTHER FINANCING ARRA_4

DEBT AND OTHER FINANCING ARRANGEMENTS - Schedule of Long-Term Debt (Details) - USD ($) $ in Thousands	Sep. 28, 2024	Dec. 30, 2023
Debt Instrument [Line Items]
Finance leases	$ 31,116	$ 28,550
Total debt and finance leases	2,341,528	2,667,368
Current portion of long-term debt	157	3,172
Current portion of finance leases	3,043	2,398
Current portion of long-term debt and finance leases	3,200	5,570
Long-term debt and finance leases	2,338,328	2,661,798
Debt discount and debt issuance costs	(11,675)	(14,651)
Long-term debt, net and finance leases	2,326,653	2,647,147
Revolving facility
Debt Instrument [Line Items]
Long-term debt, gross	$ 794,290	$ 1,129,243
Senior Notes \| 4.25% Senior Notes due 2028
Debt Instrument [Line Items]
Stated interest rate (as percent)	4.25%	4.25%
Long-term debt, gross	$ 500,000	$ 500,000
Senior Notes \| 3.75% Senior Notes due 2029
Debt Instrument [Line Items]
Stated interest rate (as percent)	3.75%	3.75%
Long-term debt, gross	$ 500,000	$ 500,000
Senior Notes \| 4.00% Senior Notes due 2031
Debt Instrument [Line Items]
Stated interest rate (as percent)	4%	4%
Long-term debt, gross	$ 500,000	$ 500,000
Other debt
Debt Instrument [Line Items]
Long-term debt, gross	$ 16,122	$ 9,575

EQUITY AND NONCONTROLLING INT_3

EQUITY AND NONCONTROLLING INTERESTS - Treasury Shares - Narrative (Details) - USD ($) shares in Millions	3 Months Ended	9 Months Ended
	Sep. 28, 2024	Sep. 28, 2024	Sep. 30, 2023	Aug. 02, 2024	Aug. 01, 2024
Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items]
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments (in shares)		0.1	0.1
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments		$ 18,400,000	$ 24,000,000
Prior Stock Repurchase Authorization
Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items]
Aggregate authorization of share repurchase program (in shares)					$ 1,300,000,000
Remaining authorized repurchase amount					$ 129,100,000
New Stock Repurchase Authorization
Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items]
Aggregate authorization of share repurchase program (in shares)				$ 1,000,000,000
Remaining authorized repurchase amount	$ 899,300,000	$ 899,300,000
Shares repurchased during period (in shares)	0.5	0.5
Stock repurchased during period, value	$ 100,700,000	$ 100,700,000

EQUITY AND NONCONTROLLING INT_4

EQUITY AND NONCONTROLLING INTERESTS - Schedule of Earnings Per Share (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Numerator:
Net income	$ 70,295	$ 88,021	$ 239,038	$ 291,418
Less: Net income attributable to noncontrolling interests	638	632	2,340	3,878
Net income attributable to Charles River Laboratories International Inc.	69,657	87,389	236,698	287,540
Calculation of net income per share attributable to Charles River Laboratories International Inc. common shareholders
Net income attributable to Charles River Laboratories International Inc.	69,657	87,389	236,698	287,540
Less: Adjustment of redeemable noncontrolling interest	379	0	1,081	0
Less: Incremental dividends attributed to noncontrolling interest holders	599	0	9,621	0
Net income available to Charles River Laboratories International Inc. common shareholders	$ 68,679	$ 87,389	$ 225,996	$ 287,540
Denominator:
Weighted-average shares outstanding - Basic (in shares)	51,394	51,283	51,461	51,199
Effect of dilutive securities:
Stock options, restricted stock units and performance share units (in shares)	189	324	252	294
Weighted-average shares outstanding - Diluted (in shares)	51,583	51,607	51,713	51,493
Anti-dilutive common stock equivalents (in shares)	746	588	505	514

EQUITY AND NONCONTROLLING INT_5

EQUITY AND NONCONTROLLING INTERESTS - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	$ 3,727,018	$ 3,257,555	$ 3,602,276	$ 2,981,078
Income tax expense (benefit)	8,348	(3,292)	848	(3,393)
Ending balance	3,787,127	3,310,761	3,787,127	3,310,761
Foreign Currency Translation Adjustment and Other
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance			(149,999)
Other comprehensive income (loss) before reclassifications			4,054
Net current period other comprehensive income (loss)			4,054
Income tax expense (benefit)			757
Ending balance	(146,702)		(146,702)
Pension and Other Post-Retirement Benefit Plans
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance			(47,167)
Other comprehensive income (loss) before reclassifications			1,038
Net current period other comprehensive income (loss)			1,038
Income tax expense (benefit)			256
Ending balance	(46,385)		(46,385)
Net Unrealized (Loss) Gain on Cash Flow Hedge
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance			739
Other comprehensive income (loss) before reclassifications			(688)
Net current period other comprehensive income (loss)			(688)
Income tax expense (benefit)			(165)
Ending balance	216		216
Total
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	(269,709)	(208,269)	(196,427)	(262,057)
Other comprehensive income (loss) before reclassifications			4,404
Net current period other comprehensive income (loss)			4,404
Income tax expense (benefit)			848
Ending balance	$ (192,871)	$ (268,066)	$ (192,871)	$ (268,066)

EQUITY AND NONCONTROLLING INT_6

EQUITY AND NONCONTROLLING INTERESTS - Nonredeemable and Redeemable Noncontrolling Interest - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended				9 Months Ended		12 Months Ended
	Jun. 30, 2022	Sep. 28, 2024	Jun. 29, 2024	Mar. 30, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023	Nov. 30, 2023	Dec. 31, 2022	Dec. 28, 2019
Schedule of Investments [Line Items]
Incremental dividends attributed to noncontrolling interest holders		$ 599			$ 0	$ 9,621	$ 0
Adjustment of redeemable noncontrolling interests to redemption value		5,705	$ 496	$ 4,807
Additional Paid-In Capital
Schedule of Investments [Line Items]
Adjustment of redeemable noncontrolling interests to redemption value		5,326	195	4,406
Retained Earnings
Schedule of Investments [Line Items]
Adjustment of redeemable noncontrolling interests to redemption value		$ 379	$ 301	401
Noveprim Group
Schedule of Investments [Line Items]
Percentage of voting interests acquired									41%
Noveprim Group
Schedule of Investments [Line Items]
Equity interest (as percent)		90%				90%
Noncontrolling interest ownership percentage		10%				10%
Contractually defined redemption value		$ 40,600				$ 40,600
Dividend fair value		8,000				8,000
Incremental dividends attributed to noncontrolling interest holders						9,600
Noveprim Group \| Additional Paid-In Capital
Schedule of Investments [Line Items]
Adjustment of redeemable noncontrolling interests to redemption value						7,200
Noveprim Group \| Retained Earnings
Schedule of Investments [Line Items]
Adjustment of redeemable noncontrolling interests to redemption value						1,100
Noveprim Group \| Minimum
Schedule of Investments [Line Items]
Contractually defined redemption value		47,000				47,000
Noveprim Group \| Maximum
Schedule of Investments [Line Items]
Contractually defined redemption value		$ 54,000				$ 54,000
Supplier
Schedule of Investments [Line Items]
Equity interest (as percent)											80%
Noncontrolling interest ownership percentage	10%										20%
Contractually defined redemption value				12,000
Additional ownership percentage acquired by parent	10%		10%
Purchase of additional equity interest	$ 15,000		$ 12,000
Supplier \| Additional Paid-In Capital
Schedule of Investments [Line Items]
Adjustment of redeemable noncontrolling interests to redemption value				$ 2,800
Vital River
Schedule of Investments [Line Items]
Equity interest (as percent)										92%
Noncontrolling interest ownership percentage								8%
Additional ownership percentage acquired by parent								8%
Payments for repurchase of redeemable noncontrolling interest								$ 4,800
Redeemable noncontrolling interest, purchase price payable								$ 24,400

INCOME TAXES - Narrative (Detai

INCOME TAXES - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
INCOME TAXES - Narrative (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Effective tax rate (as percent)	23%	22%	22.90%	21.80%
Increase in unrecognized tax benefits	$ 1.2
Unrecognized tax benefits	25.2		$ 25.2
Increase in unrecognized tax benefits that would impact effective tax rate	1
Unrecognized tax benefits that would impact effective tax rate	22.1		22.1
Accrued interest on unrecognized tax benefits	1.8		1.8
Decrease in unrecognized tax benefits that are reasonably possibly over the next twelve-month period	$ 5.1		$ 5.1

INCOME TAXES - Schedule of Prep

INCOME TAXES - Schedule of Prepaid and Accrued Tax Positions (Details) - USD ($) $ in Thousands	Sep. 28, 2024	Dec. 30, 2023
Income Tax Disclosure [Abstract]
Prepaid income tax	$ 82,153	$ 59,715
Accrued income taxes	$ 39,673	$ 38,819

RESTRUCTURING AND ASSET IMPAI_3

RESTRUCTURING AND ASSET IMPAIRMENTS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Restructuring charges	$ 30,646	$ 15,160	$ 65,600	$ 21,345
Restructuring and related cost, cost incurred	95,000		95,000
Restructuring reserve	28,657	5,018	28,657	5,018	$ 5,050	$ 1,300
Severance and Transition Costs
Segment Reporting Information [Line Items]
Restructuring charges			41,470	7,008
Restructuring reserve	27,782	$ 4,143	27,782	$ 4,143	4,175	$ 356
Accrued Compensation \| Severance and Transition Costs
Segment Reporting Information [Line Items]
Restructuring reserve	$ 28,700		$ 28,700		$ 5,100

RESTRUCTURING AND ASSET IMPAI_4

RESTRUCTURING AND ASSET IMPAIRMENTS - Schedule of Restructuring Costs by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Total	$ 30,646	$ 15,160	$ 65,600	$ 21,345
Operating Segments \| RMS
Segment Reporting Information [Line Items]
Total	4,965	965	22,580	965
Operating Segments \| DSA
Segment Reporting Information [Line Items]
Total	13,866	13,220	24,123	13,218
Operating Segments \| Manufacturing
Segment Reporting Information [Line Items]
Total	5,372	975	9,660	7,162
Unallocated corporate
Segment Reporting Information [Line Items]
Total	$ 6,443	$ 0	$ 9,237	$ 0

RESTRUCTURING AND ASSET IMPAI_5

RESTRUCTURING AND ASSET IMPAIRMENTS - Schedule of Restructuring Costs for Productivity Improvement (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Severance and Transition Costs	$ 26,536	$ 3,577	$ 41,470	$ 7,008
Asset Impairments and Other Costs	4,110	11,583	24,130	14,337
Total	30,646	15,160	65,600	21,345
Cost of services provided (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Severance and Transition Costs	12,830	2,160	20,510	5,088
Asset Impairments and Other Costs	3,482	11,418	6,516	11,418
Total	16,312	13,578	27,026	16,506
Cost of products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Severance and Transition Costs	1,783	480	2,530	534
Asset Impairments and Other Costs	650	174	11,134	2,920
Total	2,433	654	13,664	3,454
Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Severance and Transition Costs	11,923	937	18,430	1,386
Asset Impairments and Other Costs	(22)	(9)	6,480	(1)
Total	$ 11,901	$ 928	$ 24,910	$ 1,385

RESTRUCTURING AND ASSET IMPAI_6

RESTRUCTURING AND ASSET IMPAIRMENTS - Schedule of Rollforward of Severance and Transition and Lease Obligation Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Restructuring Reserve [Roll Forward]
Beginning balance			$ 5,050	$ 1,300
Expense	$ 30,646	$ 15,160	65,600	21,345
Payments / utilization			(24,682)	(3,889)
Other non-cash adjustments			(17,368)	(13,696)
Foreign currency adjustments			57	(42)
Ending Balance	28,657	5,018	28,657	5,018
Severance and Transition Costs
Restructuring Reserve [Roll Forward]
Beginning balance			4,175	356
Expense			41,470	7,008
Payments / utilization			(17,920)	(3,179)
Other non-cash adjustments			0	0
Foreign currency adjustments			57	(42)
Ending Balance	27,782	4,143	27,782	4,143
Asset Impairments
Restructuring Reserve [Roll Forward]
Beginning balance			0	0
Expense			15,999	13,269
Payments / utilization			0	0
Other non-cash adjustments			(15,999)	(13,269)
Foreign currency adjustments			0	0
Ending Balance	0	0	0	0
Other Costs
Restructuring Reserve [Roll Forward]
Beginning balance			875	944
Expense			8,131	1,068
Payments / utilization			(6,762)	(710)
Other non-cash adjustments			(1,369)	(427)
Foreign currency adjustments			0	0
Ending Balance	$ 875	$ 875	$ 875	$ 875

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) $ in Millions	Sep. 28, 2024 USD ($)
US Fish and Wildlife Service \| Pending Litigation
Loss Contingencies [Line Items]
Inventory, non-human primates	$ 27